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Abstract 
Background: Mass-screening programs are necessary to prevent or even cure colorectal 
cancer. A criticism of screening however has been the risk of patient misinterpretation of the 
result, specifically the Health Certificate Effect. The study’s aim is to examine whether a 
screening result could change the amount of health care services used in six different lifestyle 
related diseases. 
Method: A sample of 100,116 patients from the NORCCAP trial was studied from 1998 to 
2003. Each patient with one of the six lifestyle related disease groups was identified and 
tracked over the six years. A logistic panel regression method was used to see if health care 
usage in each of the six lifestyle-related disease groups changed following the screening 
outcome. Changes in disease related health care usage was compared to a control group. 
Results: Screening results did appear to change the incidence of lifestyle related diseases, 
however not all of the results could be explained by a Health Certificate Effect. Participants 
who had a negative test result did appear to be at an increased risk for required outpatient care 
for complications relating to Diabetes Mellitus and Hypertension. 
Conclusion: Attention must be paid to the effects of screening outcomes when evaluating a 
mass-screening program. This study has demonstrated that screening results can change the 
risk of requiring care for other lifestyle-related diseases.  
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1 Introduction 
Colorectal cancer is one of the most common of cancers in the Nordic countries behind breast 
and prostate cancer (Hakama et. al. 2005). The 50-74 years old incidence rates of CRC within 
the Nordic countries’ population varies from 70 to 130 per 100 000 people in females and 
more than 150 per 100 000 people in males (Hakama et. al. 2005). It is the present belief that 
the majority of CRCs occur due to a malignant transformation of an adenomatous polyp 
(McPhee & Papadakis 2008), however research points to any polyp of any size in the distal or 
proximal colon as being at risk for cancer (Imperiale et. al. 2000). Adenomatous polyps are 
lesions within the colon wall and are identified by their size, shape and general characteristics 
under a microscope. While not all of these polyps are cancerous, it is believed that they most 
commonly develop into malignant cancers.  If left untreated, 50% of all cases of CRC will be 
fatal (McPhee & Papadakis 2008). Slightly less than 50% of cancerous adenomatous polyps 
are found in the distal to splenic flexure of the colon (McPhee & Papadakis 2008).  
Figure 1: Norwegian Colorectal Cancer Incidence Age-Standardized Rate. 
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The incidence of CRC has been growing in Norway steadily in both males and females as 
reported in Figure 1. The increase does appear to be leveling off and in fact may be 
decreasing amongst the female population. 
While there has been an increase in CRC incidence in Norway, there is fortunately a reduction 
in mortality as presented below in Figure 2. This could be due to further awareness of the risk 
factors for CRC over time, specifically people with a family history who choose to participate 
in screening.  
Figure 2: Norwegian Mortality from Colorectal Cancer – Age Standardized Rate 
 
The risk of CRC incidence appears to increase with age in Norway as presented in Figure 3. 
Cases are reported as early as 30 years of age and level off at the age of 85. The curve is 
steepest between the ages of 45 and 70 years, this indicates the age at which most CRC cases 
are reported in Norway.   
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Figure 3: Norwegian Incidence Rate of Colorectal Cancer from 1990 to 2008 by Age.
 
The mortality from CRC in Norway is presented below in Figure 4. The starting age at which 
mortality is recorded appears to be slightly less the five years later than the age when reported 
cases of CRC incidence begin in Figure 3; this could demonstrate that the 5-year survival rate 
is quite poor. The steepness of the two curves in Figure 4 is also similar to those in Figure 3 
but do not peak as high. One interesting observation of note is that incidence curves peak at 
between 400 and 550 per 100,000 people while mortality peaks at between 340 and 475 per 
100,000 people, this suggests that the survival rates of CRC in Norway are low. 
Screening has been introduced as a means to improve the survival time of CRC by locating 
potentially cancerous adenomatous polyps before they turn malignant. Even if there is 
evidence of cancerous lesions within the colon and rectum, early intervention can still remove 
the cancerous areas prior to it potentially metastasizing to other regions of the body.  
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Figure 4: Norwegian Mortality Rate of Colorectal Cancer from 1990 to 2007 by Age 
 
1.1  Aim 
The prevalence and incidence of CRC has been largely linked to a country’s affluence and 
trends in lifestyle (Hakama et. al. 2005). For this reason, affluence could be an explanation for 
increasing trends in CRC within the Nordic countries. Similarly, this problem can be 
exacerbated by inadequate screening that is not backed up by educational programs involving 
information on lifestyle choices in relation to disease. With criticisms of mass screening 
programs leading to adverse events and patient misunderstanding of the results, there is an 
ever-increasing need to identify the areas of weakness in screening programs and remedy the 
persistent problems.  
There has been frequent talk about a ‘Health Certificate Effect’ as a possible reason for results 
that appear to be skewed, unexplainable or against the hypothesis. These unintended effects 
have also been linked to increased costs being incurred that could inaccurately be transferred 
to mass screening for CRC. This paper intends to explore the way that individuals perceive 
their health and the use of health services. The principle of the Health Certificate Effect will 
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be explored through the patterns exhibited by individuals participating in the NORCCAP trial 
and how their results relate to other lifestyle-related comorbidities. The main aim for this 
thesis project is to evaluate the incidence of selected lifestyle-related comorbidities and 
whether there is a change following a mass-screening program for colorectal cancer. 
This thesis will be organised as follows: a brief introduction to CRC, a discussion about 
screening aims and methods, the theories of health usage used to frame the research aims of 
this thesis, a description of the Health Certificate Effect, an introduction to the selected 
lifestyle-related disease groups, a brief discussion of the NORCCAP trial, a presentation of 
the data, an explanation of the methods used in the statistical analysis, the study’s results and, 
a brief discussion of the results and their implications.  
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2 Background 
2.1 Risk Factors 
CRC has a number of risk factors. The incidence of CRC increases with age starting at 45 
years and approximately 90% of all cases occur in individuals over the age of 50 years 
(McPhee & Papadakis 2008, Lieberman et. al. 2000, Imperiale et. al. 2000). Similar to other 
cancers, CRC does have links to family history of neoplasia that accounts for roughly 20%-
30% of all cases; it should be noted that the genes leading to the cause of these cancers have 
yet to be identified (McPhee & Papadakis 2008). There is also a proportionate link to the age 
of the affected first-degree family member. Individuals with a first-degree family member 
having CRC have an approximately two times greater risk than the general population 
(McPhee & Papadakis 2008). This relative risk is increased however if the family member 
was diagnosed with CRC at less than 45 years of age by 3.8 times, was between the ages of 
45 and 59 years of age by 2.2 times and was diagnosed above the age of 59 years by 1.8 times 
(McPhee & Papadakis 2008). Another risk factor is whether the individual has inflammatory 
bowel disease, this can increase the likelihood of an adenocarcinoma in the colon within 
seven to ten years following the onset of the patient’s Ulcerative Colitis or Crohn’s Disease. 
The cumulative risk further increases by 5% to 10% after twenty years and 20% after thirty 
years (McPhee & Papadakis 2008). Some epidemiological studies have pointed to diets that 
are rich in fats and red meats as causes for increases in the risk of CRC adenomas. Other risk 
factors include: sugar consumption, personal history of breast cancer, uterine cancer, ovarian 
cancer, physical inactivity, Diabetes Mellitus, obesity, smoking, alcohol in excess, abdominal 
radiotherapy, and ureterosigmoidostomy (Kumar & Clark 2009, Vatn & Hoff 1989). Diets 
that are high in fruits, vegetables and fibre have been shown to decrease the risk of CRC 
(McPhee & Papadakis 2008), as well as exercise (colon cancer only), aspirin and other 
NSAIDs, and combined oestrogen/progesterone hormone replacement therapy (Kumar & 
Clark 2009). Males are also more likely to suffer from colon cancer while more women tend 
to suffer from rectal cancer (Imperiale et. al. 2000), however some studies noted that polyp 
size and dysplasia are greater in women (Hoff et. al. 1984, Hoff et. al. 1985, Hoff 1987). 
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2.2 Symptoms 
There is strong support of the ademonatous polyp to CRC sequence (Hakama et. al. 2005) and 
due to the fact that adenocarcinomas are rather slow growing, it may take up to several years 
before symptoms may appear. In most cases, the characteristics of the symptoms are 
dependent upon the location of the carcinoma, however most symptoms of CRC are found for 
reasons other than polyps (Vatn & Hoff 1989). Common symptoms include chronic blood 
loss form the carcinoma location, iron-deficiency anemia (due to blood loss), obstructions in 
the colon (although this is rare), lesions causing bowel pain, changes in bowel habits, 
constipation or alternating frequencies between loose stools, blood in the stool, and in some 
rare cases, weight loss (McPhee & Papadakis 2008).  
2.3 Diagnosis 
Since CRC is a slow growing disease and largely asymptomatic, most tumours are detected 
with the use of a FOBT, Flexible Sigmoidoscopy or Colonoscopy through screening. In some 
rare cases where the colon is obstructed or sigmoidoscope/colonoscope cannot reach an area 
further in the colon such as in the cecum, a barium enema or a CT colonography would be 
used (McPhee & Papadakis 2008).  
2.4 Treatment 
The most common form of treatment is the resection of the primary colonic or rectal cancer; 
about 80% of patients undergo surgery, although fewer than half in this group survive more 
than 5 years (Kumar & Clark 2009). The use of chemotherapy and radiation therapy (adjuvant 
therapy) is also used as a treatment option, however it is largely dependent upon the tumour 
staging of the CRC (Robinson et. al. 1999). Due to the largely unclear understanding of CRC 
development, a large emphasis must then be placed on secondary diagnostics tools such as 
screening methods and awareness in order to make treatment choices possible (Vatn & Hoff 
1989). Below is a representation of CRC staging and its treatment implications based upon 
staging descriptions from McPhee & Papadakis (2008).  
1. Stage 1 (Early): Has a high 5-year survival rate of between 90% and 100%, therefore 
chemotherapy or radiation treatment is not needed (McPhee & Papadakis 2008). 
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2. Stage 2 (Middle): The 5-year survival rate is roughly 80%, treatment such as 
chemotherapy or radiation is generally not needed, however patients with a higher risk of 
CRC recurrence (perforation, poor differentiation on histology) are suggested to receive 
adjuvant treatment (McPhee & Papadakis 2008). 
3. Stage 3 (Late): Even with surgical resection, the 5-year survival rate is 20-30%, it is 
therefore recommended to provide post-surgical adjuvant therapy, which can significantly 
increase the survival rate (McPhee & Papadakis 2008). 
4. Stage 4 (Fatal): By this stage, nearly 20% of patients have the CRC metastasize to 
other regions namely the liver and lung; the 5-year survival rate is as low as 5%. 
Resection of the new metastasized areas can increase the survival rate in 35%-55% of 
cases. Approximately 20% of patients in this group respond to chemotherapy regiments 
(McPhee & Papadakis 2008). 
2.5 Method of Early Detection: Screening  
The goals of CRC screening are to reduce the incidence of mortality through early detection 
and treatment interventions, and to detect the presence of potentially malignant adenomatous 
polyps and removing them (Janz et. al. 2003, Hakama et. al. 2005).  The slow development of 
CRC taking an average of 10 years from the initial discovery of an adenoma to malignancy 
makes screening for this cancer ideal (Atkin 2002). When screened patients are compared to 
controls for survival rates of CRC, the screened group demonstrates a significantly higher 
survival rate, while those in the control group and unscreened individuals showed similar 
survival rates (Mandel et. al. 1993). It is then crucial that an early screening diagnosis is made 
in order for the CRC prognosis to improve through surgery (resection), which if caught early 
enough is considered curative (Hoff 2004). This ability to ‘cure’ and the generally slow 
development of malignancy is why polyp and CRC screening have been identified as being a 
necessary cancer to screen for (Hakama et. al. 2005).  
2.5.1 Fecal Occult Blood Test 
Of all the available screening tests, FOBT is the only method that has been tested in an 
adequately-sized Randomized Control Trial setting (Hoff 2004), the best known trials are the 
Newcastle Trial (Hardcastle et. al. 1996), The Minnesota Colon Cancer Control Study 
(Mandel et. al. 1993) and the Funen Trial (Kronborg et. al. 1996). Most CRC cancers and 
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some large adenomas result in increased chronic blood loss that may be detectable. A variety 
of FOBT tests are available to test for fecal occult blood in the stool that is linked to 
adenomatous polyps in the colon. To reduce the likelihood of false-positive tests the patient is 
asked to abstain from aspirin, NSAIDs, red meat, poultry, fish, and vegetables with peroxide 
activity (turnips, horseradish) for 72 hours; vitamin C may also give a false-positive test 
(McPhee & Papadakis 2008). The sensitivity (the ability to detect adenomatous polyps) of 
FOBT is estimated to be approximately 30% to 92% for a single screening round when testing 
for asymptomatic CRC (Hoff 2004, Towler et. al. 1998). When given to a general population, 
2%-6% of tests are positive. It is recommended that patients with a positive test should then 
undergo a colonoscopy accompanied by the removal of any potentially malignant polyps. Of 
the total positive tests, 5%-18% will have CRC and adenomatous polyps are generally 
identified in 25%-50% of patients with a positive test (McPhee & Papadakis 2008). The low 
sensitivity of FOBT for advanced neoplasia makes them a less attractive choice for 
population-based screening than endoscopic (FS or colonoscopy) or radioscopic tests (CT 
colonography). They are more suitable in settings where health care resources are limited or 
in patients who desire non-invasive methods of screening. (McPhee & Papadakis 2008).  
Table 1: Predicted Effectiveness of FOBT - Female 
 Predicted Number of Deaths  Predicted Mortality Rates 
Period Without Screening With Screening Difference  Without Screening With Screening Difference 
        
Denmark        
        
1993-1997 5661 5661 -  17.0 17.0 - 
1998-2002 5879 5434 445  17.1 15.5 1.7 
2003-2007 5962 5206 756  17.0 14.7 2.4 
2008-2012 5964 4928 1036  16.7 14.0 2.7 
2013-2017 6097 5038 1059  16.5 13.8 2.7 
        
Finland        
        
1993-1997 2880 2880 -  8.8 8.8 - 
1998-2002 3019 2793 226  8.7 7.9 0.8 
2003-2007 3123 2727 396  8.6 7.7 1.4 
2008-2012 3254 2686 568  8.4 7.0 1.4 
2013-2017 3335 2752 583  8.2 6.8 1.7 
        
Norway        
        
1993-1997 3877 3877 -  14.0 14.0 - 
1998-2002 4174 3855 319  14.3 12.8 1.5 
2003-2007 4397 3850 547  14.2 12.1 2.1 
2008-2012 4540 3673 867  13.9 11.5 2.4 
        
Sweden        
        
1993-1997 6472 6472 -  10.4 10.4 - 
1998-2002 6557 6071 486  10.0 9.0 1.0 
2003-2007 6531 5732 799  9.4 8.1 1.4 
2008-2012 6388 5270 1118  8.7 7.3 1.5 
2013-2017 6101 5029 1072  7.9 6.6 1.3 
        
(Adapted from Hrsitova & Hakama 1997). 
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The use of this method for screening is highly sensitive to attendance which is required every 
second year, as attendance decreases its cost-effective advantage over the other tests is 
weakened; at 50% compliance the cost-per-death prevented is similar to FS, and Colonoscopy 
(Lieberman 1995). An overall reduction in mortality of CRC using this method has been 
estimated to be between 7% and 33% (Towler et. al. 1998, Mandel et. al. 1993). The main 
benefit to the use of FOBT is the fact that is relatively easy to administer (in the comforts of 
home), it shows to have high individual compliance and it is inexpensive (Hardcastle et. al. 
1996).  
Table 2: Predicted Effectiveness of FOBT - Male 
 Predicted Number of Deaths  Predicted Mortality Rates 
Period Without Screening With Screening Difference  Without Screening With Screening Difference 
        
Denmark        
        
1993-1997 5070 5070 -  22.1 22.1 - 
1998-2002 5099 4622 477  21.5 19.3 2.2 
2003-2007 5147 4406 741  20.9 17.9 3.0 
2008-2012 5194 4290 904  20.2 16.9 3.4 
2013-2017 5296 4373 923  19.8 16.5 3.3 
        
Finland        
        
1993-1997 2354 2354 -  12.9 12.9 - 
1998-2002 2634 2383 251  13.0 11.8 1.2 
2003-2007 2948 2516 432  13.1 11.3 1.8 
2008-2012 3267 2689 578  12.9 10.7 2.2 
2013-2017 3595 2956 639  12.8 10.6 2.2 
        
Norway        
        
1993-1997 4174 4174 -  21.8 21.8 - 
1998-2002 4602 4187 415  23.6 21.2 2.4 
2003-2007 5075 4367 708  25.4 21.7 3.6 
2008-2012 5686 4718 968  27.4 22.9 4.5 
        
Sweden        
        
1993-1997 6490 6490 -  14.4 14.4 - 
1998-2002 6647 6045 602  14.1 12.6 1.5 
2003-2007 6723 5758 965  13.6 11.5 2.0 
2008-2012 6744 5528 1216  12.8 10.6 2.2 
2013-2017 6709 5495 1214  11.8 9.8 2.0 
        
(Adapted from Hrsitova & Hakama 1997). 
Research by Hrsitova and Hakama has attempted to predict the gains of screening using a 
FOBT with a predicted 20% effectiveness for detecting CRC as presented in Table 1 and 
Table 2. The assumption in this model is that the screening program is started in the mid-
1990s. The numbers are predicted and are a measurement of CRC related deaths in screened 
and non-screened individuals set against an age-adjusted ‘world standard mortality’ rate 
(Hristova & Hakama 1997). In all countries there is an expected mortality rate drop in CRC of 
between 0.8 and 3.4, which is not large but has a better result than mammography, which 
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already has a mandatory screening program in place in all four countries. There is also a trend 
(with exception for Norway which isn’t present) that in the final year category of 2013-2017 
that the mortality reduction slows, this is related to expected decrease in the number of people 
having CRC as the years progress through the positive effects of screening. 
2.5.2 Flexible Sigmoidoscopy (FS) 
The use of a 60 cm flexible sigmoidoscope permits visualization of the rectosigmoid and 
descending colon where approximately 50% of all CRCs are located (McPhee & Papadakis 
2008, Hakama et. al. 2005). This screening method can be performed within a physician’s 
office or clinic, it requires an easy to follow bowel preparation prior to the test and is a 
relative short test to administer (Hakama et. al. 2005). The use of FS has a sensitivity of 70% 
for detecting adenomatous polyps and advanced neoplasia (Hoff 2004). The long-term follow-
up findings of the Telemark Polyp Study demonstrated an 80% reduction in CRC incidence 
(Hoff 2004). Adenomatous polyps are identified in 10%-20% of patients and CRC is detected 
in 1% of patients. Case-control studies suggest that screening sigmoidoscopy programs lead 
to a 60% to 80% reduction in CRC mortality (McPhee & Papadakis 2008). The risk of serious 
complications (perforation) associated with FS is less than 1 in 10 000 patients, however 
approximately 50% of advanced neoplasms (cancer, adenomas ≥ 1cm, polyps with villous 
histology or high-grade dysplasias) are proximal to the splenic flexure and are therefore above 
the reach of a FS examination (McPhee & Papadakis 2008). A frequent barrier to compliance 
using this screening method is the complaint of some degree of discomfort, although the 
procedure itself can take between 5 and 10 minutes (Segnan et. al. 2002, Gondal et. al. 2003). 
In the SCORE trial, 60.4% of patients experienced mild discomfort and 2% described the pain 
as being severe (Segnan et. al. 2002). This screening method also does not require as frequent 
screening as with FOBT, in fact follow-up intervals with removed adenomatous polyps in 
‘average-risk’ individuals will not likely effect the incidence of CRC (Thiis-Evensen et. al. 
2001). There is also a risk of perforation using this method that can cause infection, bleeding 
or further aggravation of any existing lesions (Hakama et. al. 2005). 
2.5.3 Colonoscopy 
The Colonoscopy screening method permits examination of the entire colon, for this reason 
this is the gold standard in screening of patients, it has an estimated sensitivity for detecting 
CRC of greater than 90% (Hoff 2004). This screening method is largely reserved for those 
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deemed to be at high risk due to a positive familial history of CRC or a positive test for 
lesions in a less sensitive test such as FOBT or FS because of the time costs of the test, the 
risk of perforation, and the use of sedation (Lieberman et. al. 2000, Hakama et. al. 2005). In 
asymptomatic individuals between 50 and 75 years of age undergoing screening colonoscopy, 
the prevalence of advanced neoplasia is 6-11% and of cancer is 1%. However there have yet 
to be Randomized Control Trials on the use of colonoscopy as a screening tool in regards to 
CRC mortality or incidence (Hoff 2004). The incidence of serious complications is close to 
0.1% (Lieberman et. al. 2000). This method of screening in one study was demonstrated to 
detect the risk of potential CRC in 73.3% of patients prior to distal spread and nodal 
involvement (Lieberman et. al. 2000). Although it is the most sensitive test, polyps that are 
behind folds, or that are small and flat can be easily missed, therefore this should be done 
after optimal bowel preparation (McPhee & Papadakis 2008, Imperiale et. al. 2000); this 
optimal bowel preparation required has also been identified as being a major barrier to 
screening attendance (Hakama et. al. 2005). Similar to FS, Colonoscopy does carry a risk of 
perforations, while it is rare, some episodes are described as hazardous (Robinson et. al. 
1999); the review of the literature within this project did not find any link of colonoscopy to a 
fatality. 
2.5.4 Concerns of Screening Catchment 
A large concern in deciding which CRC screening method to use is concerned with desire to 
use a test with a high degree of sensitivity, a low cost to administer, a maximum convenience 
for health provider and patient alike, and an ability to collect a high number of individuals 
(Hakama et. al. 2005). There is continual conflict between all the above factors and Figure 5 
demonstrates a model of this concern. Screening studies are sensitive to attendance rates, 
which are reliant upon an individual’s response to knowledge about the program or the 
method in question (Hoff 2004).  
The broken line in the model demonstrates an ideal situation where a test was able to detect 
100% of lesions and CRC; such a test does not yet exist (Hoff 2004). Due to the fact that there 
is no ‘perfect test’, a combination of methods would be required in order to achieve the 
desired 100% in the model. However, with each test added, there is a risk of decreasing the 
attendance rate. The solid line demonstrates the actual diagnostic yield where those with a 
familial predisposition which would give the test initially high pick-up rates for lesions (Hoff 
2004). At the other end of the model are those individuals within the high lifestyle risk group 
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who ‘reluctantly comply’ (Hoff 2004), and would be the last to join the screening and most 
likely to be the most sensitive to attendance rates (Whynes et. al. 2003). It is thus imperative 
to catch those who are highest risk to reduce CRC incidence. A further concern related to 
catchment is the detection of polyps and appropriate action following the finding of 
adenomatous polyps. It has been found that in general, greater than 90% of adenomatous 
polyps do not progress to malignancy (Hakama et. al. 2005). The high number of non-
cancerous adenomatous polyps has created challenges in finding an appropriate test with high 
efficacy that will still catch the maximum number of at-risk individuals but not produce 
unnecessary resource cost.  
Figure 5: Hoff’s Theoretical Catchment Attendance Patterns Based on Patient Risk 
 
 
 
 
 
 
                                       (Figure from: Hoff 2004) 
2.6 Cost Component 
The necessity to screen presents a cost component as well for health care services. While 
much emphasis has been placed on the test costs, there is further the cost associated with 
treating cancer when compared to screening. For a health program to be put into place, such 
as a mass screening for CRC, the program must be demonstrated to be cost-effective. The 
associated costs must first be known; this may include the financial cost but also the potential 
consequences of the program (Drummond et. al. 2005). There must also be a weighing of 
various options, for example, ‘what are the costs of action (screening) vs. inaction 
(treatment)?’ It is known that a large share of medical costs are incurred in the final months of 
the patient’s life, it is thus important to use screening as a tool to reduce cancer costs which 
could be incurred within end-of-life care (Howard et. al. 2009). Therefore patients who do not 
attend screening programs can incur a massive cost and resource burden on the health system. 
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Patients who have their potentially malignant polyps discovered at an early stage incur lower 
lifetime medical costs when compared to those with undetected polyps (Howard et. al. 2009). 
Thus for screening to accurately be evaluated, one would need to have the information of 
various courses of action available in terms of their costs and consequences (Drummond et. 
al. 2005).  
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3 Theoretical Framework 
An underlying principle surrounding participation and non-participation in a screening 
program surrounds the belief of the study’s invitees. These frameworks have been used as an 
explanation to determine reasons for certain health behaviours among the sample used in this 
thesis. To explain this phenomenon this thesis will combine tenets of the ‘Health Belief 
Model’ by Janz and Becker, and Rosenstock’s ‘Use of Health Services Model’.  
3.1 Rosenstock’s Determinants of Health Behaviour 
Rosenstock examines the use of health services in terms of groups with certain characteristics. 
In general, it is concluded that people who most often use preventative or detection services 
(such as a screening) are younger to middle-aged, female, are highly educated, and earning a 
high income (Rosenstock 2005). A similar trend is seen in the use of diagnostic and treatment 
services such as a visit to the dentist or physician. This trend is explained through what 
Rosenstock describes as ‘motivation for perception and action’ in that if one is unconcerned 
with a particular aspect of their health, they are unlikely to take any action that could have 
some bearing on that aspect (Rosenstock 2005). For example, if one believes that they are 
unlikely to come into contact with a given disease, they would then not see it as being 
justifiable to take measures to prevent it or act upon it. This draws onto Rosenstock’s three 
components of his ‘Determinants of Health Behaviour’ in terms of potential cancer screening 
and detection program barriers.  
3.1.1 The health motive or threat 
This component comprises two dimensions. The first dimension is whether the individual 
believes that they are susceptible to the given disease and the second is whether the threat 
from the given disease would have serious implications on the individual (Rosenstock 1963). 
Therefore, the individual most believe that they are at risk for the given disease and that by 
not acting there could be serious implications. The higher the perceived susceptibility and the 
higher the perceived threat, the more likely the individual will act.  
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3.1.2 Belief about the utility of various courses of action in reducing 
the health threat 
In this component the motive and threat are established, however the individual must also 
believe that the course of action available to solve this threat can reduce the likelihood of it 
occurring and also reduces the potential seriousness of the problem (Rosenstock 1963). The 
individual must further believe that undertaking these actions will not increase or lead to 
further threats (Rosenstock 1963), in other words the individual must believe that the course 
of action is safe and will lead to positive outcomes. With respect to a screening test for cancer, 
the individual must first believe that they are suffering from cancer regardless of whether 
symptoms are present (Rosenstock 1963). Building upon this assumption, the individual must 
believe that existing methods available can detect cancer (both symptomatic and 
asymptomatic) and that by having the cancer detected earlier, there will be a better cancer 
prognosis (Rosenstock 1963). Lastly, the individual must also believe that the facilities, 
personnel and methods available are competent to both employ and administer these tests 
(Rosenstock 1963).  
3.1.3 Conflicts among motives and courses of action 
This is described as when motives, their beliefs and the proposed courses of action of these 
motives are in conflict with each other. These must then be resolved in order for a behaviour 
or response to emerge (Rosenstock 1963). An example of this is if the individual is motivated 
to take a certain response to improve their health well-being but may be drawn away on acting 
upon it by unpleasant factors (embarrassment), potential pain, inconvenience, emotionally 
upsetting experiences or an unwanted expense (Rosenstock 1963). The individual could also 
believe that the health professional would be unable to reconcile these fears; the risk in this 
belief is that the individual could then believe that the motive for action is no longer important 
enough. Thus for the individual to act in this case, the perceived benefit must outweigh the 
perceived ‘cost’. The individual must then also be convinced that the need for action is 
necessary as delaying the action risks decreasing the level of motivation.  
3.1.4 Inducing Behavioural Change 
Rosenstock claims that there is a rather large error that public health officials have failed to 
rectify, in that in the context of screening programs for chronic disease, individuals are asked 
to recognize signs and factors of various diseases in differing ways (Rosenstock 1963). This 
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poses a number of problems in that it assumes or demands that the lay public has a knowledge 
of human physiology and medicine, it places the lay person in position where they must 
decide which tests are needed or which specialist to see, and lastly that each screening 
program appeal will lose its message among those who are not concerned with it so program 
appeals will then have to often be repeated.  
If barriers to action are based upon individual responses to readiness to behave, determined 
beliefs, psychological barriers, interpersonal influences and critical incidents, it would thus be 
in the public’s interest to simply minimize the barriers to action (Rosenstock 2005). This can 
be done through increasing the chances to act and providing better cues for trigger responses, 
this can be done through reducing financial costs (publicly funded screening), distances to 
travel to screening (mobile screening programs) or setting hours of operation that are 
convenient (scheduling an appointment) (Rosenstock 2005). Similarly trigger responses (cues 
to action) can be as simple as reminders from physicians to patients or announcements and 
stories in the mass media (Rosenstock 2005).  
Therefore Rosenstock concludes that three conditions must be met for an individual to act in a 
prevention or detection program: 
1. The individual must be ready to take action relative to a particular health condition, 
based on susceptibility and serious consequences 
2. The individual believes that the test or preventative method in question is feasible and 
appropriate to the desired outcomes; thus reducing susceptibility and threat 
3. There must be a cue or stimulus to trigger the response. 
While efforts to minimize barriers and maximize convenience to the public are keys to 
screening acceptance, there will always be a group that remains that is either not 
psychologically ready to act or will not respond to cues to seek various health services no 
matter how they are presented (Rosenstock 2005). In the context of the NORCCAP study, one 
could expect that those who were invited to screening but did not attend would be in this 
group where they lacked a trigger or cue to act. It would then be expected that these Non-
Attendee people could be the most at risk for lifestyle related diseases.  
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3.2 The Health Belief Model (HBM) 
The HBM was designed as a means to explain reasons behind the failure of individuals to 
accept preventative and screening initiatives as a means of early disease detection for 
asymptomatic disease (Janz & Becker 1984). The HBM consists of four principle tenets 
described below in Figure 6: 
Figure 6: Janz and Becker’s ‘Health Belief Model’ 
 
(Figure adapted from Janz & Becker 1984) 
1. Perceived Susceptibility: This describes how vulnerable an individual may feel 
towards a particular disease and how great of a risk may be felt of contracting the 
particular disease 
2. Perceived Severity: This is a personal measure of the individual in regards to the 
seriousness of the disease. This measure includes medical consequences (death, pain, 
disability) and social consequences (inability to work, social relations, family life). 
3. Perceived Benefits: This highlights the fact that while an individual may acknowledge 
the seriousness and susceptibility of disease there must also be an available course of 
action to reduce the threat of the specific disease. The course of action must also prove to 
be beneficial (feasible and efficacious) to the individual in order for them to accept the 
action available.  
Demographic Variables 
(age, sex, race, ethnicity, etc.) 
Sociopsycholoical Variables 
Perceived benefits of preventation action 
Minus 
Peceived barriers to preventative 
action 
 
Likelihood of Taking 
Recommended Preventative 
Health Action 
Perceived Threat of Disease 
’X’ 
Perceived susceptibility to disease 
’X’ 
Perceived Seriousness (Severity) 
of Disease ’X’ 
 
Cues to Action 
Mass Media Campaigns 
Advice from Others 
Reminder Postcard from physicians or dentist 
Illness of family member or friend 
Newspaper or Magazine articles 
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4. Perceived Barriers: Some health actions may have potentially negative aspects 
associated with it, and these negative aspects act as barriers to intended health behaviours. 
The individual prior to undertaking a health action will weigh the costs and benefits of 
their actions, and should the potential ‘costs’ outweigh the benefits, the individual may 
choose not to act. Identified barriers could be the financial expense, pain, embarrassment 
caused by the procedure, inconvenience or unwanted side effects. 
The final tenet of ‘Perceived Barriers’ appears to be the strongest barrier to CRC screening 
compliance using this framework. In a study carried out by Janz et. al. the opinions and 
attitudes of individuals towards screening and CRC were collected through a series of 
telephone interviews (2003). The primary reason for respondents not participating in 
screening was the barrier of ‘embarrassment’ of undertaking FOBT, FS and Colonoscopy. 
The degree to which respondents saw the various preventative measure to CRC in terms of 
everyday life was a strong predictor of screening participation (Janz et. al. 2003). Similar to 
the conclusions presented by Rosenstock (2005), the authors conclude that more must be done 
to inform all sectors of screening and health effects in CRC awareness campaigns. It is 
through education campaigns and ‘physician-guided’ promotion that perceived barriers to 
CRC screening will be removed (Janz et. al. 2003: 633).  
3.2.1 Behaviours 
In the screening context, it is of utmost importance to have a high degree of participation in 
order to both increase the possibilities of identifying asymptomatic patients with a certain 
disease and to increase the efficacy of a particular test. However, using the HBM framework 
the majority of participants are those who are already of the opinion that they are at particular 
risk of the disease being screened. This theory has been demonstrated by the general trend 
that the vast majority of participants in screening are those who view themselves as being at 
risk or have been identified as being at risk; more specifically risk due to a family member 
having a similar ailment (Janz & Becker 1984). Similarly, research in this area has 
demonstrated that those who are married (or common law relationship) tend to view 
‘susceptibility’ and ‘severity’ more strongly and act upon these beliefs through higher 
screening participation (Janz & Becker 1984).  
The study of HBM also extends to ones view of healthy lifestyle behaviour, a common 
example of this would be views on smoking. With countless links and media campaigns 
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demonstrating the effects of smoking upon ones life expectancy and overall health well-being, 
it is very apparent that a HBM is in effect in this case as well. Those who do not see a link 
between smoking habits and various acute and chronic disease risks are more likely smokers 
themselves while those who identify themselves as ‘non-smokers’ link smoking to disease. 
Therefore in the HBM context, one could conclude that a smoker would view the barriers of 
smoke cessation as being greater than the susceptibility and seriousness of diseases related to 
smoking (Janz & Becker 1984).  
Due to the fact that HBM is largely associated with psychological behaviour it is important to 
identify limitations of the model: some behaviours are habitual which could hinder health 
related behaviour, many health behaviours are undertaken for non-health reasons (for example 
appearance), economic/environmental factor could prevent an individual from a health 
behaviour although they may believe it to be beneficial, and the model assumes that health is 
important to individuals and that cues to action are widely available; in some instances that is 
not the case (Janz & Becker 1984).  
3.3 Summary 
Both the ‘trigger’ model presented by Rosenstock and the HBM model presented by Janz & 
Becker demonstrate the psychological processes behind screening programs and the health of 
individuals. Similarly, there is a challenge in trying to bring in individuals who are of lower-
socioeconomic status who are traditionally least likely to attend a screening (Hardcastle et. 
al.1986); this emphasizes the need to maximize ‘uptake from all sections of the community’ 
(Atkins 2002: 1298). Both models acknowledge that for an individual to act, they first must 
believe that their action is necessary for the well-being of themselves. The models further 
demonstrate that for these actions to occur various opportunities to remedy these concerns 
must be available and must be demonstrated to be effective. Lastly, both models emphasize 
the necessity that education through means of physicians, health professionals, mass media 
and screening programs must provide opportunities for individuals to take an active role in 
their own health decisions by presenting clear facts to individuals (Janz et. al. 2003, Hoff 
2004). It is within this ‘lack of necessary education’ that adverse events can occur within a 
mass-screening program, leading to what is described in the following section as the Health 
Certificate Effect. 
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4 The Health Certificate Effect (HCE) 
The ‘Health Certificate Effect’ is a concept that is concerned with the interpretation of a 
health result by an individual and is identified as a major obstacle within screening programs 
(Robinson et. al. 1999, Thiis-Evensen et. al. 2006). The primary concern with this effect is 
that in the context of a screening program for a specific disease, a negative test could be 
wrongly interpreted as meaning that the individual is ‘healthy’. Further, the screening result 
could be misunderstood that the negative result is a clean bill of health and risky lifestyles 
choices such as smoking or intake of unhealthy foods could ‘justifiably’ continue (Tymstra & 
Bieleman 1987). While there is emphasis on the need to screen for preventable or manageable 
disease, the practice of mass screening risks presenting unintended consequences such as the 
HCE which can hinder the effectiveness of a mass screening program. 
In a study by Tymstra and Bieleman to assess the effects of mass screening for cardiovascular 
disease, they introduce a practical example of potential mass screening consequences (1987). 
For the most part, patients with a positive test result for cardiovascular disease were induced 
to change certain risky health behaviours such as smoking cessation, partaking in physical 
activity or improving dietary choices. However, there was a group of patients with a 
favourable test result (negative test) who led particularly unhealthy lifestyles yet it did not 
affect their results (Tymstra & Bieleman 1987). Unfortunately these results did not induce 
lifestyle change and was in most part regarded as meaning that the results of the screening 
were a ‘justification of their unhealthy behaviour’ (Tymstra & Bieleman 1987: 290).  
Similar results were observed in the Telemark Polyp Study where the leading cause of death 
in both their sample group and control group was coronary heart disease (Hoff et. al. 2000). In 
the NORCCAP study (which followed the Telemark Polyp Study), a HCE was also suspected 
and the authors pointed out a possible circumstance where patients had a sense of ‘being taken 
care of’ through screening services leading to a situation where detrimental lifestyle choices 
will continue and efforts to increase awareness of possible unhealthy practices will be largely 
ignored; specifically smoking habits (Larsen et. al. 2007: 477, Hoff et. al. 2000). Those who 
were invited to the CRC screening had a reduced intake of fruits and vegetables, did not 
increase their frequency of physical activity, had a higher weight gain and demonstrated no 
improvement in their smoking habits when compared to the study’s control group (Larsen et. 
al. 2007, Hoff 1987, Hoff et. al. 2000). A similar HCE was also discovered in findings from 
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the Telemark Polyp Study in their 13-year follow up which demonstrated a general sense of 
well-being amongst the screenees with negative findings which lasted for approximately 1 
year following the study (Hoff et. al. 2001). 
Smoking has also been shown to significantly increase the number of colorectal polyps when 
compared to those who do not smoke (Hoff et. al. 1987). For this reason smoking and obesity 
were primary risk factors used in seeking to identify and explain a presence of a ‘Health 
Certificate Effect’. To continue on with this analysis, a selection of lifestyle related conditions 
were selected in the following section. Observations in the rates of reported incidents in the 
various disease groups were observed in those who were invitees who attended the 
NORCCAP trial (positive and negative test), those who declined to attend, the control group 
and the group of excluded individuals. The selected lifestyle-related disease groups all have 
strong relations to diet, smoking status, exercise and obesity, which are all similar lifestyle 
factors studied in the post-NORCCAP analyses.  Links have also been drawn between one’s 
intake of fat, protein and low intake of fibre to the development of polyps (Vatn & Hoff 
1989), which could share some similar characteristics to other disease groups. Similarly, the 
follow-up study of Larsen et. al. also made the observation that participants in the trial with 
advanced neoplasia had a poorer lifestyle than those in the control group (2006a, 2006b), it 
could then be explored if these same risk factors also showed increased frequency in also 
disease groups listed in the proceeding section compared between screenees and controls. 
4.1 Expected Model 
If a Health Certificate Effect were present, the method used in this study should be able to 
accurately demonstrate whether or not adverse effects of screening could be explained by the 
results. An illustration of the potential hypothetical result is given below in Figure 7.  
Figure 7 demonstrates the purpose of the statistical model. Given the incidence path of 
disease X, it would be expected that the control would be a constant rate for the given disease 
since they would not be affected by a screening result ‘shock’. Those who were screened, 
should an adverse screening effect be present, would be expected to have a change in 
incidence of disease differing from the constant. The intervention may either ‘shock’ the 
individual into adopting a negative or positive lifestyle change. A positive lifestyle change 
following the screening intervention would be expected to lead to a decrease in incidence 
illustrated by the royal blue (3) arrow. A negative lifestyle change, would be associated with 
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an increase in the incidence of disease X at a higher rate than that of the constant as illustrated 
by the yellow (1) arrow.  
Figure 7: Model of the Health Certificate Effect 
 
 
(3) 
 
 
 
In the context of this study, it would be predicted that those within the Negative Findings and  
Non-Attendee groups would be at risk of being affected by the Health Certificate Effect as 
illustrated by the yellow arrow (1). This would mean that the invitees who had a Negative 
Finding or Non-Attendee would deem themselves as being healthy, but could in fact be 
suffering from another medical condition; this could be known or unknown to the participant. 
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5 Lifestyle-Related Disease Groups 
5.1 Diabetes Mellitus (DM)  
Diabetes Mellitus is a chronic syndrome of hyperglycaemia (when an excess of glucose is 
circulating around the body), which is due to the inability to break down glucose because of 
insulin deficiency, resistance or a combination of both factors (Kumar & Clark 2009). Effects 
of this disease are irreversible and its late effects can lead to the onset of coronary heart 
disease, peripheral vascular disease and stroke, hypertension and neuropathy (Kumar & Clark 
2009, McPhee & Papadakis 2008). The disease is divided into two groups, Type 1 and Type 
2. Type 1 is a disease of insulin deficiency where glucose cannot be broken down; this disease 
is more commonly referred to as ‘Juvenile Diabetes’ as it will manifest itself between early 
childhood and puberty.  
Type 2 is common in populations of more affluent societies. Circulating insulin is sufficient 
to prevent ketoacidosis but increasingly becomes unable to prevent hyperglycaemia; over time 
this trend leads to insulin resistance within the body (McPhee & Papadakis 2008). This 
disease can remain subclinical or undiagnosed for many years before diagnosis, with 25% to 
50% of patients already showing signs of vascular complications at the time of diagnosis 
(Kumar & Clark 2009). Obesity can increase the risk of diabetes by 80-100 times (Kumar & 
Clark 2009) with present waist-to-hip ratios greater than 0.9 in men and 0.8 in women also 
being associated with increased risk of diabetes in obese subjects (McPhee & Papadakis 
2008). When diabetes is diagnosed in a man between the ages of 40 and 59, their life 
expectancy will be reduced by 5-10 years (Kumar & Clark 2009). This form of diabetes is 
preventable through a proper diet and physical activity, and in some cases the effects can even 
be reversed (Kumar & Clark 2009).  
5.2 Hypertension & Secondary Hypertension 
Hypertension or as it is more commonly referred to as ‘High Blood Pressure’ is identified as 
an elevated arterial systolic blood pressure that is ≥ 140 mm Hg or a diastolic blood pressure 
of ≥ 90 mm Hg (McPhee & Papadakis 2008). Hypertension is present in roughly 20% to 30% 
of the population (Kumar & Clark 2009) and if left untreated can dramatically increase the 
risk of stroke, coronary heart disease, peripheral vascular disease, end-stage renal disease, and 
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heart failure (McPhee & Papadakis 2008). As blood pressure rises, there is in increased risk of 
mortality and morbidity, for example isolated systolic hypertension can lead to a 2 to 3 -fold 
increase in cardiac mortality (Kumar & Clark 2009). Hypertension is divided into two 
categories, Primary and Secondary. The onset of Primary Hypertension occurs between 25 
and 50 years of age and can be due to a number of genetic and environmental factors such as; 
sympathetic nervous system hyperactivity, abnormal cardiovascular or renal development, 
rennin-angiotensin system activity, defect in natriuresis, intracellular sodium and calcium, and 
certain exacerbating factors such as obesity, intake of sodium in ones diet, alcohol 
consumption, cigarette smoking, stress and amount of exercise (Kumar & Clark 2009, 
McPhee & Papadakis 2008).  
The smaller group of Secondary Hypertension is identifiable in those showing signs of 
hypertension prior to 25 years of age, those showing sudden symptoms after 50 years of age 
or those suddenly not responding to earlier hypertension treatments (McPhee & Papadakis 
2008). Secondary Hypertension is largely due to other conditions that can increase blood 
pressure in the body for example, renal diseases alone account of 80% of all Secondary 
Hypertension cases (Kumar & Clark 2009).  
Identifiable signs of hypertension include a high blood pressure or a different pressure 
between different extremities (arms and legs), narrowing of the retinas, a left ventricular 
heave, and a weak or delayed pulse (McPhee & Papadakis 2008). 
5.3 Chronic Obstructive Pulmonary Disease (COPD) 
COPD is the combination of syndromes (emphysema, asthma and bronchitis) that cause 
permanent destruction to the lung and obstruction to airflow (Kumar & Clark 2009). The 
presence of Chronic Bronchitis or Emphysema is most often link to the progression of 
obstruction in COPD (McPhee & Papadakis 2008). Long-term exposure to toxic particles and 
gases are the leading causes for the onset of COPD; cigarette smoke accounts of 90% of these 
cases in developed countries (Kumar & Clark 2009). It is predicted by 2020 that COPD will 
account for the fifth most cause of disability worldwide and the third leading cause of death 
(Kumar & Clark 2009). Similarly, infections related to the lower respiratory tract, such as 
COPD, accounts for 10% of the worldwide burden of morbidity and mortality and 75% of the 
worldwide antibiotic usage (Kumar & Clark 2009).  
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COPD is most often identified by a persistent cough with white or clear spitum, as well as 
wheezing and breathlessness; these symptoms can be further worsened by cold weather, 
atmospheric pollution and foggy weather (Kumar & Clark 2009). Symptoms are usually 
present for ten years or more and are diagnosed in patients between the ages of 50 and 60 
(McPhee & Papadakis 2008). The disease can further progress to where everyday day 
activities such as walking or getting dressed leads to breathlessness. When these factors are 
combined they can lead to or further progress other diseases such as hypertension, 
osteoporosis, depression, and metabolic problems (weight-loss, loss of muscle mass) (Kumar 
& Clark 2009).  
There are a number of drug therapy treatments to manage the symptoms of COPD however it 
is imperative that smoking be ceased as it can slow down the rate of lung and bronchial 
deterioration, therefore prolonging death (Kumar & Clark 2009, McPhee & Papadakis 2008).  
5.4 Ischemic Heart Disease (IHD) 
This group is characterized by a group of diseases most commonly referred to as ‘coronary 
heart disease’ in the heart that are due to an imbalance of oxygen and other nutrients and the 
demand for these substance (Kumar & Clark 2009). This could be due to factors that could 
reduce coronary flow to the heart such as: atheroma, thrombosis, spasm, embolus, coronary 
ostial stenosis, coronary arteritis and hypotension (Kumar & Clark 2009). They are a result of 
prolonged atherosclerotic plaque causing blood and nutrients to improperly circulate to certain 
parts of the heart; leading to permanent damage (McPhee & Papadakis 2008, Kumar & Clark 
2009). The disease can be classified as being with ST or without ST elevation; diagnosed 
using an Electrocardiogram (ECG). Patients with ST elevation require immediate reperfusion 
therapy that is meant to remove a blockage through the use of a stent. Patients without ST 
elevations are predominantly older, already have a pre-existing vessel disease, and have a pre-
existing vascular disease; this group is of high risk of death following hospital discharge 
(McPhee & Papadakis 2008). This group of heart diseases is the number one cause of death 
worldwide.  
Symptoms include an intense building pain, sudden weakness, cold sweats, light-headedness, 
and sudden death (this occurs in 50% of patients prior to arriving at the hospital due to 
ventricular fibrillation) (McPhee & Papadakis 2008). It should be noted however, that up to 
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one-third of patients with IHD do not have an episode detected until they undergo an ECG 
(McPhee & Papadakis 2008).  
Traditional risk factors include increased age, gender as men have a higher incidence, family 
history, smoking, diet, obesity, hypertension, Diabetes Mellitus and a sedentary lifestyle 
(Kumar & Clark 2009).  
5.4.1 Angina Pectoris (AP) 
The onset of Angina Pectoris is due to atherosclerotic (thicken of artery walls) heart disease 
and is largely characterized as darting, gripping, heavy, tight or knife-like pains (McPhee & 
Papadakis 2008, Kumar & Clark 2009). The pain is central/retrosternal but may also be felt in 
the jaw and arm, this pain can range from mild discomfort to severe pain (Kumar & Clark 
2009). This pain can be brought on by physical exertion, anger, vivid stress-inducing dreams, 
or in some instances, even at rest (Kumar & Clark 2009).  
Signs following an attack usually indicate elevated systolic and diastolic blood pressure, a 
gallop heart rhythm, and ventricular/supra-ventricular arrhythmias (McPhee & Papadakis 
2008), however diagnosis is largely based on patient history (Kumar & Clark 2009). AP can 
be a result of or a cause of other disease such as Diabetes Mellitus, Hypertension, or 
peripheral vascular disease (McPhee & Papadakis 2008).  Treatment of AP includes the 
management of other pre-existing conditions such as Diabetes and Hypertension, smoking 
cessation, weight loss, treatment for high cholesterol, and regular exercise (Kumar & Clark 
2009). Prognosis of Angina Pectoris is very good as annual mortality is < 2% (Kumar & 
Clark 2009).  
5.4.2 Acute Myocardial Infarction (AMI) 
Acute Myocardial Infarction is similar to the symptoms and signs of AP, however while AP is 
largely stress related, a myocardial infarction is a sudden attack that can occur at any time. 
Many incidents of AMI occur at rest and may only be picked up by patterns on an ECG. This 
sudden ‘attack’ is more commonly referred to a ‘Heart Attack’ where a portion of the heart 
has died because of atherosclerotic heart disease (Kumar & Clark 2009). Further, 1 in every 6 
attacks ends in sudden death as the first, last and only symptom (Kumar & Clark 2009). 
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6 Data 
6.1 Norwegian Colorectal Cancer Prevention 
(NORCCAP) Trial 
This study provided the sample of participants and controls used in this thesis. The results 
from this trial became the bulk of the focus for this thesis, specifically the finding groups. A 
brief description of the trial is described below. 
The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study was a 
prospective controlled study with the aim of undertaking a large scale screening to gain 
information about the prevalence, attendance rates, and distribution of colonic neoplasms in 
the age-risk population of individuals 50 to 64 years of age (Bretthauer et. al. 2002, Gondal et. 
al. 2003). A sample of 20,780 men and women with a ratio of 1:1 were drawn from 
populations in the urban Oslo area and the mixed rural/urban county of Telemark1 were 
placed into the intervention group; a control group of 79,808 people was also established from 
these counties and were not invited to participate in screening but shared similar 
characteristics are the invited for screening group. Both screening and control groups were 
selected at random from the Norwegian Patient Registry. Those in the intervention group 
were randomized to either a once-only FS or a combination of a once-only FS and a FOBT 
screening test. Intervention group members were also informed of the study background, the 
aim of the research, the benefits of the trial, the various risks associated with participation in 
the trial and the procedures involved in the examinations (Bretthauer et. al. 2002). The 
sampling from the FOBT arms was done no earlier than 10 days prior to the FS appointment 
and was collected from three stool samples (Bretthauer et. al. 2002). Exclusion for this trial 
included those who had previous colorectal surgery, ongoing radiation or cytotoxic therapy 
for malignant disease, severe chronic cardiopulmonary disease, life-long anticoagulant 
therapy, a coronary episode or cerebrovascular incident within the last 3 months, disabled, 
unable to give written informed consent, resident abroad, unknown address or deceased 
(Bretthauer et. al. 2003).  
 
                                                
1 Telemark Polyp Study results and trial described in Hoff et. al. 2000. 
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Table 3: Screening Method – Patient Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure adapted from Gondal et. al. 2003) 
In the FS arm of the trial, all visualized lesions within the colon were biopsied but not 
removed. For this reason, a diagnosis of an adenoma was only made after a histopathological 
examination of the biopsied lesion. The study assumed that all polyps that were ≥ 10 mm 
were defined as being positive as well as any biopsied specimen identified as being a 
neoplasia; these positive findings were referred for a colonoscopy. In the FOBT arm of the 
trial, a test must have more than 3 windows used to be valid and one positive test window was 
referred for colonoscopy (Gondal et. al. 2003). Individuals who did not have a plausible 
reason for a positive result were asked to repeat their test and if the results continued, and 
were then referred to a specialist in gastroenterology.  
The total population of the screened group is shown in Table: 3 (Gondal et. al. 2003). The 
breakdown between gender, age, and screening type (FS or FS/FOBT) are fairly similar, 
however there were more participants from Telemark (71%) than from Oslo (58%). A total of 
20,780 individuals were invited however 777 were excluded according to the study’s 
exclusion criteria which left 20,003 individuals eligible, however only a total of 12,290 
invitees took part (Bretthauer et. al. 2003). There were n = 2639 participants who had a 
  FS Only FS & FOBT 
Total  6,694 6,266 
Gender    
 Male 3,256 3,043 
 Female 3,438 3,233 
Age    
 50 – 54 years 2,308 2,099 
 55 – 59 years 2,705 2,479 
 60 – 64 years 1,681 1,688 
    
Area    
 Telemark 3,740 3,484 
 Oslo 2,954 2,782 
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positive on either the FS or FOBT, and of that group n = 2524 attended a follow-up 
colonoscopy (Larsen et. al. 2006b).  
6.2 Description of the Data 
Data for use in this project was collected in conjunction with NPR data of patients within the 
NORCCAP trial consisting of both controls and invitees. Further patient information was also 
provided by the Norwegian Cancer Registry and SSB. This data encompassed 6 years of 
information between the years of 1998 and 2003. The various data sources were then 
combined and identified using assigned patient numbers. This data included information 
concerning patient CRC screening outcomes, socioeconomic status, education, year of 
admission to hospital, ICD 9 and 10 coding, hospital code, county location of screening, civil 
status, age, birth country, and type of care received (inpatient or outpatient). Due to the fact 
that multiple data sources were combined, there was a risk of duplicate patients presented in 
the data set. The data was then cleaned to remove duplicate patient records and patients were 
then divided between the type of care received either outpatient and inpatient hospital care.  
To study the aims of this thesis, patients were then identified using ICD-9 and ICD-10 code 
grouping on the basis of disease selected for study that were identified as being associated 
with patient lifestyle. The data set was narrowed to 6 disease groups that were selected based 
upon their ICD-9 or 10 coding, these diseases included Diabetes Mellitus, COPD, 
Hypertension, Angina Pectoris, Acute Myocardial Infarction and Ischemic Heart Disease. A 
patient had to have either a main diagnosis and/or a maximum of three secondary diagnoses of 
within the selected ICD-9 or 10 codes to remain in the data sample. For example, a patient 
may have a main diagnosis of Diabetes Mellitus, and only a third secondary diagnosis with a 
relevant ICD-9 or 10 codes. Should a patient have multiple diagnoses of the same coding 
within the same year, it was only recorded once for that year. However, having a COPD 
coding for example, in one year would be recorded again and counted again if it appeared 
following the initial diagnosis in the following year. All patients who did not fulfill the ICD-9 
or 10 disease coding requirements were removed from the sample. A list of the disease groups 
and their coding are included in the Appendix I.  
Variables used within this analysis are listed and described below in Table 4 and observations 
were used from NPR data between the years of 1998 and 2003. 
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Table 4: Description of the Data Variables 
Variable Description Observation 
Year 
Age 1999 The age of the patient corresponding to their age in 1999. 1999 
Age 
Squared 
The age in 1999 variable was squared in order to determine the steepness of 
the change in age and the shape of the curve 
 
lnssb The assigned patient number identifier; it does not correspond to their real 
national number 
 
Income Patient income is listed in both a figure in Norwegian Kroner (NOK) and 
divided into groupings from (1) 0 – 99 999, (2) 100 000 – 199 999, (3) 200 
000 – 299 999, (4) 300 000 – 399 999, (5) 400 000 – 599 000, and (6) 600 
000 + 
1999 
Education The level of education attained at 1999, divided by low <10 years, 
intermediate < 14 years, and high > years. 
1999 
Birth 
Country 
Patients were recorded as either being born in Norway or being born 
abroad 
1999 
County There were two principle counties in the study of either Oslo or Telemark, 
however a third ‘Other’ group was established for those residing in a 
different county. 
 
Intention to 
Treat 
This group was divided into controls and those invited to the screening 1999,2000,2001 
Findings 
Group 
This group includes controls, attendance to screening with a positive test for 
CRC, a positive test for adenomatous polyps or a negative test, those who 
did not attend, those with returned mail or died, and those who were 
excluded due to the exclusion criteria of the NORCCAP study. 
1999,2000,2001 
Civil Status This group was divided into single, married, common-law, widow, separated 
and divorced 
1999 
Gender  Male or Female.  
Year The time dimension within the statistical model 1998-2003 
 
Below in Table: 5 are the descriptive figures of the data used in this study. There were 
identical characteristics observed between the outpatient and inpatient group. The percentages 
are listed in proportion to the total sample in the outpatient and inpatient groups. With regards 
to the disease proportions, there were differences within the two treatment care categories; it 
was for this reason that a separation of inpatient and outpatient groups was made. While there 
is evidence of patients requiring care within both the inpatient and outpatient setting, the 
majority of treatments for Diabetes Mellitus and COPD were handled in the outpatient setting. 
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This separation is important to maintain should further work study a cost component of 
screening outcomes.  
Table 5: Individual Patient Characteristic of the Data Sample 
Data Characteristics    
  Outpatient Inpatient 
Age 1999    
 50 - 54 years 51.6% 51.6% 
 55 - 64 years 48.4% 48.4% 
    
Education Low 24.2% 24.2% 
 Intermediate 47.1% 47.1% 
 High 28.7% 28.7% 
    
Income Level 1 13.5% 13.5% 
 Level 2 25.3% 25.3% 
 Level 3 32.4% 32.4% 
 Level 4 14.2% 14.2% 
 Level 5 8.7% 8.7% 
 Level 6 5.1% 5.1% 
    
Civil Status Single 11.4% 11.4% 
 Married 59.8% 59.8% 
 Common-law 3.8% 3.8% 
 Widow 20.4% 20.4% 
 Separated  3.7% 3.7% 
 Divorced 0.2% 0.2% 
    
Birth Place Norway  88% 88% 
 Other 12% 12% 
    
Gender Female 50.1% 50.1% 
 Male 49.9% 49.9% 
    
Intention to Treat Control 79.4% 79.4% 
 Invited 20.6% 20.6% 
    
Findings Groups Control 79.4% 79.4 
 Attended - CRC 0.004% 0.004% 
 Attended - POS 2.2% 2.2% 
 Attended - NEG 10.6% 10.6% 
 Non-Attendee 7% 7% 
 Returned / Dead 0.4% 0.4% 
 Excluded 0.4% 0.4% 
    
County Oslo 72.7% 72.7% 
 Telemark 25.5% 25.5% 
 Other 0.9% 0.9% 
    
Average Number of Cases per Year    
 Diabetes Mellitus 732 436 
 Hypertension 686 800 
 COPD 429 353 
 Angine Pectoris 332 510 
 AMI 40 242 
 IHD 532 620 
    
Total Number of Patients in Sample  100,116 100,106 
 
A detailed breakdown of the proportion of patients within the two different screening age 
groups is located in Appendix II. Each table is arranged according to the lifestyle-related 
disease group and all figures are measured as ‘proportion of cases per 1000 people’. 
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7 Methods 
The dataset was prepared for statistical analysis using a method called Logistic Panel 
Regression. Using Logistic Panel Regression allows changes within the six disease groups to 
be studied over time. Each patient number, given by ‘lnrssb’ in the dataset, is repeated 6 times 
representing the six years of data provided (1998-2003) for each year. This required changing 
each variable category of finding group, civil status, education, income and disease diagnosis 
by year into individual binary outcomes. It was assumed throughout the analysis that zero was 
to represent ‘not present’ and one was to represent ‘present’. This statistical analysis was used 
because of its ability to easily measure the probability of changes over time in a variety of 
independent variables on the given dependent variable of Disease Group ‘x’. The goal of this 
study was to measure survival time following a treatment within the NORCCAP trial patients, 
over intervals given by t = time in years (Hosmer & Lemeshow 1989). The formula for the 
fitting of the independent variables is given as (1) below. The following formula 
demonstrated the fitting of the variables when specifying for random effects. This formula 
represents the probability of being at a hospital department (inpatient or outpatient) given by h 
with a specific disease given by d for the given independent variables given by i at time 
interval t with parameters β given x characteristics dependent upon the disease group y.  
 
€ 
Pr(yithd ≠ 0 xit ) = P(xitβ + vi)    (1) 
The second formula (2) measures the goodness of fit or the predictability of y within the 
model. Where R2 represents the deviance within the random effect panel regression model. 
The fitting of the model is found using the log likelihood from the output of the constant 
represented by loge L1 is compared to logeL1 the measures of the full model (Fox 1997). 
€ 
R2 =1− G1
2
G02
=1− loge L1loge L0
  (2) 
The third (3) formula defines rho (given by ρ) is an additional panel-level variance component 
which explains the total proportion of the total variance contributed to by the panel-level 
variance. This formula is done by taking the log of the variance             , the standard 
deviation σv is included in the output from the regressions. When ρ = 0, the panel-level data 
! 
ln("
v
2
)
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component is not important and the panel estimator is the same as the pooled estimator, called 
the logit (Stata 2007).  
€ 
ρ =
συ
2
συ
2 +σε
2
 (3)
 
The variable ‘Year’ in the dataset corresponds to the time dimension within the Logit 
Regression Model. Regressions were run assuming normal distribution and the separation of 
outpatient and inpatient data was maintained.  
There were two regressions run for each disease group in each inpatient group and outpatient 
group. A new variable was created in order to measure the time dimension of disease between 
years within the same patient dependent upon being screened or not screened. This new 
variable was labeled as “interaction” and corresponded to the seven possible screening 
findings outcomes divided by those who had their screenings in 1999, 2000 and 2001. The 
‘interaction’ variable was calculated by multiplying the ‘findings group’ variable by the 
patients who had a screening. The interaction variable was created as a means to demonstrate 
whether the screening result would result in a change in disease incidence for the given 
disease groups dependent upon the finding outcomes.  
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8 Results 
There were a total of four regressions done for each of the six lifestyle-related disease groups. 
The intention to treat group did not have an analysis using the interaction variable because the 
intention to treat variable was already accounted for in the interaction variable groups. The 
Coefficients are written in normal text and the Standard Errors are written in parenthesis in 
each of the tables. A calculation to determine the log likelihood of each regression result 
given by formula (2) in the Methods section will be written in the description of each disease 
group result as well as the ‘rho’ from formula (3) given by 
€ 
ρ .  
8.1  Diabetes Mellitus (DM) 
Results of the logistic panel regressions are given below in Table: 6. In all four of the 
regressions, 
€ 
ρ  is greater than zero therefore the variance between the panel levels is 
important.  
In regards to group findings, those in the Non-Attendee group show a significantly higher risk 
of being treated for DM than the control group within the inpatient treatment side at the 1% 
level. Those who are in the invited group with a negative screening result, show a decreased 
risk of being treated for DM at the 10% significance level in the inpatient sample group when 
compared to controls. The lone significant result in the outpatient group were those who 
occupied the returned mail or died group, which demonstrated a decreased risk of DM than 
controls; this group was a small sample. 
In the interaction category of the results, those who attended screening and had a positive or 
negative result showed 10% significance on the inpatient side; both results showed a decrease 
in incidence when compared to the control group. The non-attendee group demonstrated an 
increased risk of incidence with significance at the 10% level. The outpatient side showed 
highly significant results for increases in incidence for those who received a negative result 
and those who failed to attend the screening at the 1% level.  
The risk of incidence of being treated for DM increases with each passing year within the 
study sample, and this holds significant at the 1% level in both inpatient and outpatient 
categories. Similarly,  this same trend applies to one’s increasing age, however the 
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significance levels are different between inpatient at 10% significance and outpatient at 1%. 
The difference is partly due to the majority of treatment associated with DM being undertaken 
at the outpatient level.  
Table 6: Regression Output – Diabetes Mellitus 
Diabetes Mellitus     
  Inpatient Outpatient 
Variable Category Findings Group Intention to Treat Findings Group Intention to Treat 
      
Age Age in 1999 0.393 (.206) * 0.382 (.206) * 0.679 (.237) *** 0.633 (.234) *** 
 Age Squared -0.003 (002) -0.003 (.002) -0.006 (.002) *** -0.005 (.002) *** 
      
Year Time Measure 0.127 (.013) *** 0.127 (.013) *** 0.245 (.012) *** 0.237 (.012) *** 
      
Education Low <10 yrs. Reference 
 Intermediate <14 yrs. -0.335 (.076) *** -0.349 (.076) *** -0.193 (.092) ** -0.194 (.091) ** 
 High > 14 yrs. -1.062 (.108) *** -1.079 (.108) *** -0.450 (.115) *** -0.454 (.114) *** 
      
Income 0 - 99,999 Reference 
 100,000 - 199,999 0.132 (.099) 0.126 (.098) -0.149 (.118) -0.141 (.117) 
 200,000 - 299,999 -0.701 (.108) *** -0.723 (.108) *** -0.588 (.123) *** -0.582 (.122) *** 
 300,000 - 399,999 -0.945 (.140) *** -0.973 (.140) *** -0.887 (.156) *** -0.883 (.155) *** 
 400,000 - 599,999 -1.165 (.175)*** -1.193 (.175) *** -0.980 (.184) *** -0.973 (.182) *** 
 600,000+ -1.002 (.208) *** -1.028 (.208) *** -0.814 (.211) *** -0.807 (.210) *** 
      
Civil Status Single Reference 
 Married -0.192 (.106) * -0.214 (.106) ** -0.040 (.123) -0.041 (.122) 
 Cohabitation 0.573 (.176) *** 0.554 (.176) *** 0.540 (.213) ** 0.538 (.211) ** 
 Widowed -0.147 (.120) -0.159 (.120) -0.165 (.141) -0.170 (.140) 
 Separated -0.246 (.200) -0.259 (.200) 0.067 (.220) 0.062 (.218) 
 Divorced -1.452 (1.254) -1.476 (1.257) -1.001 (1.237) -1.001 (1.228) 
      
Birth Country Norway Reference 
 Other 0.786 (.093) *** 0.799 (.093) *** 0.967 (.108) *** 0.966 (.106) *** 
      
Gender Male Reference 
 Female  -1.115 (.075) *** -1.128 (.075) *** -1.020 (.086) *** -1.018 (.085) *** 
      
County Oslo Reference 
 Telemark  -0.077 (.083) -0.093 (.082) -0.097 (.094) -0.095 (.093) 
 Other -1.197 (.547) ** -1.199 (.549) ** -2.457 (1.291) * -2.428 (1.266) * 
      
Groups: Findings Control Reference 
 Attended - CRC 0.958 (1.334)  0.153 (1.785)  
 Attended - Positive -0.195 (.244)  -0.130 (.263)  
 Attended - Negative -0.230 (.126) *  -0.117 (.133)  
 Non-Attendee 0.330 (.119) ***  -0.008 (.146)  
 Returned Mail or Died -0.255 (.507)  -1.477 (.831) *  
 Excluded 1.635 (.357) ***  0.572 (.514)  
      
Intention to Treat Control Reference 
 Invited  0.079 (.084)  0.026 (.095) 
      
Interaction: Time Control Reference 
 Attended - CRC -20.201 (31598.79)  -20.386 (154458.2)  
 Attended - Positive -1.111 (.636) *  0.173 (.440)  
 Attended - Negative -0.420 (.241) *  0.825 (.192) ***  
 Non-Attendee 0.294 (.170) *  1.047 (.197) ***  
 Returned Mail or Died 0.134 (.843)  0.461 (1.250)  
 Excluded 0.845 (.426) **  -0.295 (1.297)  
      
R2 = Log Likelihood  0.133 0.134 0.310 0.310 
      
ρ = rho  0.733 0.735 0.891 0.888 
*** significant at a 1% level, ** significant at a 5% level, * significant at a 10% level 
 
44 
 
Socioeconomic factors also play a major role in incidence with intermediate and high 
education, as well as income above 200,000 NOK showing a decreased chance in being 
treated for DM with significance at the 1% and 5% levels. Those who are not born in Norway 
show an increased risk of DM incidence than those born in Norway. Men have a higher risk in 
incidence than women; both variables are at the highest significance level. In the Civil Status 
category, only those occupying the Cohabitation variable showed an increased risk of being 
treated for DM at the 5% level. However, married people on the inpatient side appeared to 
have their risk of DM reduced at the 10% level. While those living in a county other than 
Oslo or Telemark do show a lower incidence of being treated for DM, the sample is too small 
of draw any conclusions and their home county is unknown. 
8.2  Hypertension 
The results of the regressions for Hypertension are described below in Table: 7. In all four 
regressions ρ was greater than zero, which means that the variance between panel levels is 
important. 
The group findings showed that those in the inpatient wing who attended the screening with a 
negative test were less likely than controls to be treated for complications related to 
Hypertension than controls, this was at the highest significance level. When the interaction 
variable was added, results for those who attended the screening in the inpatient wing were all 
significant. Those who had a CRC result were at an increased risk than controls to have 
Hypertension complications, while those with positive or negative tests where shown to have 
a decreased risk of Hypertension complications. On the outpatient side, only those with a 
negative result at screening showed a decreased risk when compared to controls. 
The risk of being treated for complications associated with Hypertension increases with age 
and the risk increases as years in the trial progress. Similar trends are observed for patients in 
both the inpatient and outpatient groups suggesting that various complications can be treated 
in both types of care within this disease group.  
Socioeconomic factors are also present in this group and demonstrate that education and 
income levels are highly significant in the incidence of Hypertension. Education was highly 
significant in reducing the chances of being treated for Hypertension when compared to 
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controls at the 1% levels within the inpatient group; it did not prove to be significant at any 
level in the outpatient group. The results within the regression for income prove to be more  
Table 7: Regression Output  - Hypertension 
Hypertension     
  Inpatient Outpatient  
Variable Category Findings Group Intention to Treat Findings Group Intention to Treat 
      
Age Age in 1999 0.325 (.117) *** 0.328 (.117) *** 0.610(.138) *** 0.594 (.138) *** 
 Age Squared -0.002 (.001) ** -0.002 (.001) ** -0.005 (.001) *** -0.005 (.001) *** 
      
Year Time Measure 0.173 (.009) *** 0.175 (.009) *** 0.181 (.010) *** 0.178 (.010) *** 
      
Education Low <10 yrs. Reference 
 Intermediate <14 yrs. -0.186 (.045) *** -0.191 (.045) *** 0.065 (.057) 0.069 (.057) 
 High > 14 yrs. -0.553 (.059) *** -0.560 (.059) *** -0.049 (.068) -0.044 (.068) 
      
Income 0 – 99,999 Reference 
 100,000 – 199,999 0.195 (.061) *** 0.196 (.061) *** 0.227 (.081) *** 0.236 (.081) *** 
 200,000 – 299,999 -0.081 (.064) -0.085 (.063) 0.315 (.080) *** 0.326 (.080) *** 
 300,000 – 399,999 -0.180 (.079) ** -0.186 (.078) ** 0.266 (.095) *** 0.277 (.095) *** 
 400,000 – 599,999 -0.365 (.095) *** -0.371 (.095) *** 0.288 (.107) *** 0.300 (.107) *** 
 600,000+ -0.326 (.113) *** -0.334 (.113) *** 0.450 (.121) *** 0.461 (.121) *** 
      
Civil Status Single Reference 
 Married 0.113 (.064) * 0.109 (.064) * 0.118 (.074) 0.123 (.074) * 
 Cohabitation 0.208 (.109) * 0.200 (.109) * 0.278 (.129) ** 0.276 (.129) ** 
 Widowed 0.053 (.072) 0.049 (.072) -0.093 (.085) -0.095 (.085) 
 Separated 0.117 (.114) 0.112 (.114) 0.149 (.131) 0.147 (.131) 
 Divorced 0.452 (.418) 0.450 (.418) 0.125 (.506) 0.131 (.506) 
      
Birth Country Norway Reference 
 Other -0.117 (.063) * -0.120 (.063) * -0.218 (.077) *** -0.227 (0.077) *** 
      
Gender Male Reference 
 Female  -0.543 (.042) *** -0.551 (.041) *** -0.403 (.049) *** -0.398 (.049) *** 
      
County Oslo Reference 
 Telemark  0.114 (.046) ** 0.112 (.045) ** -0.010 (.055) 0.0002 (0.055) 
 Other -0.480 (.270) * -0.480 (.270) * -0.334 (.280) -0.348 (.281) 
      
Groups: Findings Control Reference 
 Attended – CRC -0.026 (.885)  -0.544 (1.253)  
 Attended – Positive 0.160 (.120)  -0.013 (.149)  
 Attended – Negative -0.162 (.068) ***  -0.007 (.073)  
 Non-Attendee -0.020 (.075)  -0.122 (.094)  
 Returned Mail or Died -0.452 (.373)  -1.209(.622) *  
 Excluded 0.856 (.215) ***  0.652 (.285) **  
      
Intention to Treat Control Reference 
 Invited  -0.067 (.048)  -0.003 (0.057) 
      
Interaction: Time Control Reference 
 Attended - CRC 2.599 (1.032) **  -21.994 (170068.6)  
 Attended - Positive -0.700 (.325) **  0.158 (.364)  
 Attended - Negative -0.621 (.173) ***  0.430 (.151) ***  
 Non-Attendee 0.081 (.148)  0.305 (.203)  
 Returned Mail or Died 0.609 (.684)  -20.751 (50457.12)  
 Excluded 1.103 (.307) ***  0.818 (.617)  
      
R2 – Log Likelihood  0.040 0.040 0.070 0.070 
      
ρ = rho  0.515 0.516 0.610 0.611 
*** significant at a 1% level, ** significant at a 5% level, * significant at a 10% level 
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difficult to interpret. Within the inpatient group, the results would suggest that incidence of 
Hypertension would increase at the 100,000 to 199,999 NOK level, while a decrease in 
incidence would be expected for those in the sample with an income of 300,000 NOK and 
above. The polar opposite occurs within the outpatient group however, which showed that the 
risks of Hypertension increase at all income levels at the highest significance levels. Civil 
status was significant for those who were married and in cohabitation in both groups showing 
an increased risk of Hypertension complications on both treatment type sides. Gender was 
also highly significant with women having a significantly lower risk of Hypertension 
complications than men. Birth country also proved to be significant with the Norwegian born 
population showing a higher risk of Hypertension than foreign born populations. 
8.3  Chronic Obstructive Pulmonary Disease (COPD) 
The results of the regressions for COPD are described below in Table: 8. In all four of the 
regressions ρ was greater than zero, which means that the variance between panel levels is 
important. 
In the findings group variable those who attended the screening with a negative result were 
significant on both treatment sides with a reduced risk of COPD than the control group. The 
invitees who did not attend were at increased risk of COPD on the inpatient side. The 
excluded group was highly significant on the inpatient and outpatient side within the findings 
group; this variable will be explained in further detail within the discussion.  
Age did not appear to have any significance on the inpatient side, however it was significant 
at the 5% level on the outpatient side. The year variable was significant at the highest level 
and increased the risk of COPD with each passing trial year at both patient levels.  
The socioeconomic variables showed highest significance on the inpatient side. Income above 
200,000 NOK was attributed to a decreased risk of COPD, while income in the 100,000 to 
199,999 NOK range showed an increased risk over the reference group. A similar trend was 
seen on the outpatient side for increased risk in the same income group, however only income 
of 400,000 NOK and above was shown to have a significant decrease. Education proved to be 
a significant factor in all 4 regressions at the highest significance level and led to a decreased 
risk in COPD over the low education group. Women were also less likely than men to have  
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Table 8: Regression Output – Chronic Obstructive Pulmonary Disorder 
COPD     
  Inpatient Outpatient  
Variable Category Findings Group Intention to Treat Findings Group Intention to Treat 
      
Age Age in 1999 0.221 (.243) 0.225 (.244) 0.554 (.242)** 0.542 (.240) ** 
 Age Squared -0.001 (.002) -0.001 (.002) -0.004 (.002) * -0.004 (.002) * 
      
Year Time Measure 0.167 (.015) *** 0.165 (.015) *** 0.247 (.014) *** 0.244 (.014) *** 
      
Education Low <10 yrs. Reference 
 Intermediate <14 yrs. -0.687 (.085) *** -0.705 (.085) *** -0.462 (.086) *** -0.466 (.085) *** 
 High > 14 yrs. -1.743 (.145) *** -1.772 (.146) *** -1.658 (.141) *** -1.667 (.140) *** 
      
Income 0 - 99,999 Reference 
 100,000 - 199,999 0.320 (.109) *** 0.313 (.109) *** 0.437 (.120) *** 0.441 (.119) *** 
 200,000 - 299,999 -0.830 (.125) *** -0.860 (.125) *** -0.037 (.126) -0.044 (.125) 
 300,000 - 399,999 -1.110 (.175) *** -1.145 (.176) *** -0.220 (.163) -0.232 (.162) 
 400,000 - 599,999 -1.182 (.226) *** -1.214 (.227) *** -0.396 (.207) * -0.397 (.205) * 
 600,000+ -2.366 (.405) *** -2.415 (.408) *** -1.049 (.308) *** -1.050 (.305) *** 
      
Civil Status Single Reference 
 Married -0.349 (.130) *** -0.380 (.131) *** 0.035 (.134) 0.023 (.132) 
 Cohabitation 0.581 (.198) *** 0.551 (.199) *** 0.572 (.210) *** 0.547 (.208) *** 
 Widowed 0.585 (.137) *** 0.569 (.137) *** 0.711 (.142) *** 0.698 (.141) *** 
 Separated 0.340 (.219) 0.322 (.219) 0.417 (.225) * 0.410 (.223) * 
 Divorced 0.434 (.987) 0.417 (.994) 0.600 (.898) 0.591 (.895) 
      
Birth Country Norway Reference 
 Other -0.633 (.139) *** -0.631 (.139) *** -0.372 (.132) *** -0.372 (.131) *** 
      
Gender Male Reference 
 Female  -0.452 (.084) *** -0.470 (.084) *** -0.380 (.083) *** -0.386 (.082) *** 
      
County Oslo Reference 
 Telemark  0.231 (.092) ** 0.226 (.092) ** -0.188 (.095) ** -0.185 (.094) ** 
 Other -0.650 (.567) -0.639 (.570) -2.193 (.857) *** -2.175 (.850) ** 
      
Groups: Findings Control Reference 
 Attended - CRC -19.397 (11642.7)  -22.866 (38638.53)  
 Attended - Positive -0.224 (.276)  -0.282 (.273)  
 Attended - Negative -0.334 (.144) **  -0.408 (.143) ***  
 Non-Attendee 0.346 (.135) ***  0.044 (.144)  
 Returned Mail or Died -0.707 (.694)  -1.708 (1.003)  
 Excluded 2.838 (.334) ***  2.488 (.430) ***  
      
Intention to Treat Control Reference 
 Invited  0.138 (.096)  -0.109 (.098) 
      
Interaction: Time Control Reference 
 Attended - CRC 22.185 (11642.7)  0.431 (.136)  
 Attended - Positive 0.517 (.422)  0.570 (.519)  
 Attended - Negative 0.158 (.228)  0.173 (.284)  
 Non-Attendee 0.116 (.205)  -0.111 (.295)  
 Returned Mail or Died 1.583 (.844) *  1.975 (1.394)  
 Excluded -0.524 (.453)  0.219 (.624)  
      
R2 = Log Likelihood  0.160 0.160 0.195 0.197 
      
ρ = rho  0.755 0.760 0.809 0.805 
*** significant at a 1% level, ** significant at a 5% level, * significant at a 10% level 
 
COPD complications at the highest significance level in both inpatient and outpatient. A 
similar result was also shown in the birth country variable, where those born outside of 
Norway had a decrease risk of being treated for COPD than those born in Norway.  Those in 
the county of Telemark had an increased risk of suffering from COPD than those in Oslo on 
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the inpatient side, while the opposite was true on the outpatient side. The civil status variable 
showed increased risk of COPD complications in the cohabitation and widowed groups in 
both treatment groups at the highest significance level, however in the inpatient group it was 
observed that those who were married had a decreased risk of COPD at the highest 
significance level. Those who were separated showed an increased risk of COPD on the 
outpatient side at the 10% significance level. 
8.4  Angina Pectoris (AP) 
The results of the regressions for AP are discussed below in Table 9. In all four of the 
regressions ρ was greater than zero, which means that the variance between panel levels is 
important. 
Those who were invited for screening appeared to have a decreased risk of requiring 
treatment for AP, this was only observed on the outpatient side and was at the lowest 
significance level; this observation did not occur in the inpatient group. There were no 
significant results on the inpatient side within the findings group and only those with a 
negative screening result and those who did not attend screening had significant results at the 
10% level that resulted in a decrease on the outpatient side. When the interaction variable was 
included, only the excluded group had significant results at the 5% level in both treatment 
cases resulting in an increase in treatment for AP. 
The age variable was only significant at the 10% level in the outpatient group, which resulted 
in an increase in the treatment for AP. The year variable was highly significant, but only on 
the outpatient side. Risks of AP appeared to only increase on the outpatient side but not the 
inpatient side, this may suggest that treatment is largely handled by outpatient care. 
A strong effect was seen within the socioeconomic variables. Education was highly 
significant in both care groups, which resulted in a decrease in risk of requiring AP care as 
education increases when compared to the low education group.  Those study members who 
occupied the income group of 100,000 to 199,999 NOK were highly significant on both sides 
of the treatment care and were at increased risk of requiring treatment for AP. Decreases in 
AP care were observed from 300,000 NOK above in the inpatient group, while decreases in 
AP were only observed starting at the 400,000 NOK and above income level. Those who were 
male, lived in Telemark and were born outside of Norway had a significantly increased risk of 
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requiring care in both the inpatient and outpatient group. Similarly, those who were married, 
in cohabitation, widowed and separated were all at a significantly higher risk of requiring care 
for AP than those who were single in both the inpatient and outpatient groups. 
Table 9: Regression Output – Angina Pectoris 
Angina Pectoris     
  Inpatient Outpatient  
Variable Category Findings Group Intention to Treat Findings Group Intention to Treat 
      
Age Age in 1999 0.082 (.167) 0.082 (.167) 0.327 (.180) * 0.315 (.180) * 
 Age Squared 0.0001 (.001) 0.0001 (.002) -0.002 (.002) -0.002 (.002) 
      
Year Time Measure -0.014 (.012) -0.015 (.012) 0.106 (.014) *** 0.104 (.014) *** 
      
Education Low <10 yrs. Reference 
 Intermediate <14 yrs. -0.343 (.063) *** -0.348 (.063) *** -0.171 (.069) ** -0.173 (.069) ** 
 High > 14 yrs. -0.854 (.086) *** -0.858 (.086) *** -0.533 (.091) *** -0.531 (.091) *** 
      
Income 0 - 99,999 Reference 
 100,000 - 199,999 0.334 (.090) *** 0.339 (.090) *** 0.391 (.099) *** 0.385 (.099) *** 
 200,000 - 299,999 -0.111 (.094) -0.114 (.094) 0.103 (.103) 0.095 (.102) 
 300,000 - 399,999 -0.470 (.117) *** -0.476 (.116) *** -0.073 (.124) -0.084 (.123) 
 400,000 - 599,999 -0.579 (.137) *** -0.584 (.137) *** -0.377 (.151) ** -0.386 (.151) *** 
 600,000+ -0.545 (.162) *** -0.548 (.161) *** -0.420 (.182) ** -0.427 (.181) ** 
      
Civil Status Single Reference 
 Married 0.583 (.102) *** 0.582 (.102) *** 0.459 (.109) *** 0.461 (.109) *** 
 Cohabitation 1.003 (.162) *** 0.991 (.162) *** 0.406 (.187) ** 0.397 (.187) ** 
 Widowed 0.573 (.112) *** 0.568 (.112) *** 0.495 (.119) *** 0.495 (.119) *** 
 Separated 0.950 (.157) *** 0.945 (.157) *** 0.623 (.173) *** 0.628 (.173) *** 
 Divorced 0.633 (.633) 0.634 (.634) 0.802 (.626) 0.804 (.626) 
      
Birth Country Norway Reference 
 Other 0.267 (.082) *** 0.264 (.082) *** 0.212 (.090) ** 0.207 (.090) ** 
      
Gender Male Reference 
 Female  -1.529 (.065) *** -1.531 (.065) *** -1.068 (.067) *** -1.071 (.067) *** 
      
County Oslo Reference 
 Telemark  0.139 (.065) ** 0.143 (.065) ** 0.513 (.068) *** 0.513 (.067) *** 
 Other -0.614 (.387) -0.613 (.388) -0.150 (.373) -0.145 (.373) 
      
Groups: Findings Control Reference 
 Attended - CRC -17.559 (4624.384) -28.280 (1170670) 
 Attended - Positive -0.099 (.184)  -0.248 (.193)  
 Attended - Negative -0.058 (.096)  -0.191 (.101) *  
 Non-Attendee -0.003 (.106)  -0.222 (.118) *  
 Returned Mail or Died -0.623 (.501)  0.169 (.440)  
 Excluded 1.605 (.270) ***  1.090 (.287) ***  
      
Intention to Treat Control Reference 
 Invited  0.020 (.068)  -0.125 (.073) * 
      
Interaction: Time Control Reference 
 Attended - CRC -0.011 (11323.17)  0.185 (.400)  
 Attended - Positive -0.288 (.355)  0.460 (.429)  
 Attended - Negative -0.098 (.167)  0.198 (.229)  
 Non-Attendee 0.254 (.167)  0.240 (.272)  
 Returned Mail or Died -0.711 (1.136)  -28.245 (1169321)  
 Excluded 0.708 (.348) **  1.116 (.529) **  
      
R2 = Log Likelihood  0.089 0.090 0.053 0.054 
      
ρ = rho  0.649 0.651 0.589 0.590 
*** significant at a 1% level, ** significant at a 5% level, * significant at a 10% level 
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8.5 Acute Myocardial Infarction (AMI) 
The results of the regressions for AMI are discussed below in Table: 10. In all four of the 
regressions ρ was greater than zero, which means that the variance between panel levels is 
important. 
With respect to the findings group, those who attended the screening with a negative result 
were significant on both the inpatient and outpatient side resulting in a decrease in AMI risk. 
Those who were non-attendees had a lower risk of AMI on the outpatient side with 
significance at the 10% level. Those who were invited to screening (ITT) had a lower risk of 
AMI at the 5% level than controls, however the number of people in this group is small. 
When the interaction variable was included, the only significant groups were those who 
attended the screening with a positive test and those with a negative, their risk were both 
decreases on the inpatient side only.  
The risk in suffering from an AMI is significant and increases with age in both inpatient and 
outpatient categories at the 5% and 10% level. In regards to the year variable, as the study 
progresses the risk of being treated for AMI decreases in the inpatient group, but increases in 
the outpatient group. This could be explained by the much lower sample group within the 
outpatient group compared to the inpatient; although the number of patients suffering from an 
AMI is low when compared to the other lifestyle-related diseases in this study.  
Education at the intermediate and high levels resulted in significantly lower risk on the 
inpatient side with both variables have significance at the 1% level. On the outpatient side, 
only the high education group resulted in a decrease in the risk of AMI at the 5% level. 
Income was a contributing factor to a decrease in AMI on the inpatient side from 300,000 
NOK and up, while income did not have any significance on the outpatient side. All the 
categories of civil status resulted in an increase in AMI when compared to those who were 
single on the inpatient side with exception to those who occupied the divorce group. Women 
were at a decreased risk than men on both the inpatient and outpatient side and those residing 
in Telemark were more likely to suffer from an AMI than those in Oslo at the 1% level.  
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Table 10: Regression Output – Acute Myocardial Infarction 
Acute Myocardial Infarction     
  Inpatient Outpatient  
Variable Category Findings Group Intention to Treat Findings Group Intention to Treat 
      
Age Age in 1999 0.283 (.168) * 0.278 (.167) * 0.993 (.445) ** 1.000 (.445) ** 
 Age Squared -0.002 (.002) -0.002 (.002) -0.008 (.004) ** -0.008 (.004) ** 
      
Year Time Measure -0.039 (.016) ** -0.037 (.016) ** 0.068 (.039) * 0.069 (.039) * 
      
Education Low <10 yrs. Reference 
 Intermediate <14 yrs. -0.256 (.062) *** -0.264 (.062) *** -0.034 (.169) -0.030 (.169) 
 High > 14 yrs. -0.738 (.087) *** -0.749 (.087) *** -0.493 (.216) ** -0.488 (.216) ** 
      
Income 0 - 99,999 Reference 
 100,000 - 199,999 0.001 (.091) 0.002 (.091) -0.208 (.246) -0.190 (.246) 
 200,000 - 299,999 -0.096 (.093) -0.106 (.092) -0.134 (.240) -0.114 (.240) 
 300,000 - 399,999 -0.290 (.113) *** -0.303 (.112) *** -0.368 (.290) -0.348 (.290) 
 400,000 - 599,999 -0.308 (.130) ** -0.317 (.130) ** -0.117 (.311) -0.096 (.311) 
 600,000+ -0.576 (.170) *** -0.588 (.170) *** 0.287 (.329) 0.302 (.329) 
      
Civil Status Single Reference 
 Married 0.240 (.097) ** 0.230 (.097) ** 0.305 (.253) 0.312 (.253) 
 Cohabitation 0.654 (.159) *** 0.641 (.159) *** 0.594 (.432) 0.588 (.432) 
 Widowed 0.364 (.106) *** 0.358 (.106) *** 0.405 (.277) 0.399 (.276) 
 Separated 0.399 (.158) ** 0.394 (.158) ** 0.234 (.436) 0.231 (.436) 
 Divorced -0.690 (1.012) -0.696 (1.012) -19.889 (33659.08) -22.041 (99192.8) 
      
Birth Country Norway Reference 
 Other -0.010 (.087) -0.009 (.086) 0.214 (.208) 0.200 (.208) 
      
Gender Male Reference 
 Female  -1.394 (.068) *** -1.401 (.068) *** -1.492 (.181) *** -1.489 (.180) *** 
      
County Oslo Reference 
 Telemark  0.306 (.063) *** 0.302 (.063) *** -0.007 (.173) 0.011 (.172) 
 Other -0.001 (.325) 0.001 (.325) 0.206 (.744) 0.206 (.744) 
      
Groups: Findings Control Reference 
 Attended - CRC 0.422 (1.034)  -20.392 (74389.88)  
 Attended - Positive 0.001 (.174)  -0.154 (.449)  
 Attended - Negative -0.167 (.101) *  -0.586 (.292) **  
 Non-Attendee 0.078 (.103)  -0.638 (.341) *  
 Returned Mail or Died -0.182 (.460)  -20.536 (26206.11)  
 Excluded 1.082 (.242) ***  1.003 (.637)  
      
Intention to Treat Control Reference 
 Invited  -0.046 (.067)  -0.502 (.197) ** 
      
Interaction: Time Control Reference 
 Attended - CRC -18.725 (25435.11)  -0.011 (.276)  
 Attended - Positive -2.048 (1.015) **  -20.039 (30558.27)  
 Attended - Negative -0.504 (.275) *  0.698 (.644)  
 Non-Attendee 0.074 (.223)  -19.407 (16094.16)  
 Returned Mail or Died -18.195 (8740.974)  0.006 (81873.9)  
 Excluded 0.203 (.510)  -21.139 (74786.77)  
      
R2 = Log Likelihood  0.001 0.001 0.009 0.009 
      
ρ = rho  0.228 0.232 0.524 0.526 
*** significant at a 1% level, ** significant at a 5% level, * significant at a 10% level 
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8.6 Ischemic Heart Disease (IHD) 
The results of the regressions for IHD are discussed below in Table: 11. In all four of the 
regressions ρ was greater than zero, which means that the variance between panel levels is 
important. 
The findings group had only one significant result at the 10% level for those who had a 
negative screening test on the inpatient side with a reduced risk of IHD complications. A 
similar result was observed for the interaction variable, with only the negative screening test 
sample showing any significance at a 10% level with their risk of IHD complications reduced 
when compared to the control group.  
Increases in the sample’s age, as well as in the progression of the study’s years resulted in an 
increased risk of IHD in both the inpatient and outpatient group at the 1% significance level; 
however the age variable in the outpatient side was only significant at the 10% level.  
Education was a significant reducing factor of IHD at the intermediate and high levels on both 
treatment sides. In regards to income level, those in the 100,000 to 199,999 NOK group had 
an increased risk of IHD complications than the reference group at the 1% level for both the 
inpatient and outpatient treatment sides. The outpatient side also had significance at the 
200,000 to 299,999 NOK income level with an increase in IHD risk at the 5% significance 
level. The risk of IHD was reduced among those with an income of 300,000 NOK and above 
with a 1% to 5% significance level, however this was only true for patients on the inpatient 
side. Those who were married, in cohabitation, widowed and separated all had an increased 
risk of IHD complications at the 1% significance level on both the inpatient and outpatient 
side. Men were also at an increased risk for IHD than women at the 1% significance level on 
both treatment sides. Those born outside of Norway were also at an increased risk of IHD 
complications at the 5% significance level, but this was only the case for those in the inpatient 
group. Those residing in Telemark were at a decreased risk for IHD complications when 
compared to the Oslo group at the 1% significance level, this was however only the case for 
the inpatient side.  
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Table 11: Regression Output – Ischemic Heart Disease 
Ischemic Heart Disease     
  Inpatient Outpatient  
Variable Category Findings Group Intention to Treat Findings Group Intention to Treat 
      
Age Age in 1999 0.533 (.183) *** 0.530 (.183) *** 0.346 (.193) * 0.337 (.193) * 
 Age Squared -0.004 (.002) ** -0.004 (.002) ** -0.002 (.002) -0.002 (.002) 
      
Year Time Measure 0.048 (.011) *** 0.048 (.011) *** 0.205 (.012) *** 0.204 (.012) *** 
      
Education Low <10 yrs. Reference 
 Intermediate <14 yrs. -0.259 (.070) *** -0.267 (.070) *** -0.166 (.075) ** -0.172 (.075) ** 
 High > 14 yrs. -0.857 (.091) *** -0.863 (.091) *** -0.862 (.098) *** -0.866 (.098) *** 
      
Income 0 - 99,999 Reference 
 100,000 - 199,999 0.414 (.102) *** 0.422 (.102) *** 0.408 (.116) *** 0.423 (.116) *** 
 200,000 - 299,999 -0.034 (.105) -0.036 (.105) 0.259 (.116) ** 0.266 (.116) ** 
 300,000 - 399,999 -0.262 (.124) ** -0.269 (.124) ** -0.044 (.135) -0.042 (.135) 
 400,000 - 599,999 -0.344 (.141) ** -0.348 (.141) ** -0.065 (.151) -0.060 (.151) 
 600,000+ -0.509 (.168) *** -0.519 (.168) *** -0.226 (.179) -0.223 (.179) 
      
Civil Status Single Reference 
 Married 0.592 (.106) *** 0.593 (.106) *** 0.617 (.112) *** 0.624 (.112) *** 
 Cohabitation 1.025 (.178) *** 1.012 (.178) *** 0.775 (.203) *** 0.758 (.203) *** 
 Widowed 0.627 (.116) *** 0.626 (.117) *** 0.561 (.124) *** 0.560 (.124) *** 
 Separated 0.770 (.173) *** 0.771 (.173) *** 0.804 (.182) *** 0.802 (.182) *** 
 Divorced -0.294 (.813) -0.290 (.817) 0.205 (.741) 0.218 (.744) 
      
Birth Country Norway Reference 
 Other 0.218 (.089) ** 0.214 (.089) ** -0.027 (.099) -0.038 (.099) 
      
Gender Male Reference 
 Female  -2.120 (.074) *** -2.128 (.074) *** -2.072 (.082) *** -2.076 (.081) *** 
      
County Oslo Reference 
 Telemark  -0.193 (.073) *** -0.187 (.073) *** -0.123 (.077) -0.119 (.076) 
 Other -0.826 (.422) ** -0.806 (.421) * -0.855 (.443) * -0.870 (.446) * 
      
Groups: Findings Control Reference 
 Attended - CRC -18.741 (6406.406)  -20.716 (16359.33)  
 Attended - Positive 0.024 (.190)  -0.063 (.203)  
 Attended - Negative -0.176 (.106) *  -0.179 (.111)  
 Non-Attendee -0.014 (.115)  -0.082 (.124)  
 Returned Mail or Died -0.643 (.519)  -1.077 (.662)  
 Excluded 2.158(.283) ***  2.420 (.291) ***  
      
Intention to Treat Control Reference 
 Invited  -0.008 (.074)  -0.006 (.079) 
      
Interaction: Time Control Reference 
 Attended - CRC 0.043 (15718.26)  0.314 (56636.71)  
 Attended - Positive -0.091 (.315)  -0.892 (.632)  
 Attended - Negative -0.310 (.185) *  0.296 (.209)  
 Non-Attendee 0.191 (.169)  0.348 (.240)  
 Returned Mail or Died -0.079 (889)  -19.756 (22602.52)  
 Excluded 0.745 (.325) **  0.666 (.466)  
      
R2 = Log Likelihood  0.138 0.140 0.138 0.139 
      
ρ = rho  0.714 0.717 0.730 0.733 
*** significant at a 1% level, ** significant at a 5% level, * significant at a 10% level 
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9 Discussion 
The aim of this study was to explore the behaviours of the Norwegian population towards a 
mass screening program for CRC and whether the outcomes have an effect on the lifestyle 
related diseases of Diabetes Mellitus, Hypertension, Chronic Obstructive Pulmonary Disease, 
Angina Pectoris, Acute Myocardial Infarction and Ischemic Heart Disease. The results 
indicated that when looking at the Findings Group and Interaction Group, the group that was 
most expected to experience the Heath Certificate Effect, the Negative Findings group, did 
have significant results. It was predicted at the start of the study that the Negative Findings 
group would be the group at most risk for increases in the six disease groups due to a HCE, 
however this group experienced a general decrease in incidence when compared to the control 
group. The described decrease occurred in all the disease groups with exception to Angina 
Pectoris. There was also significance found in the Non-Attendee group that resulted in an 
increased risk for Diabetes Mellitus, Hypertension and COPD, while there was a decreased 
risk in Acute Myocardial Infarction, Angina Pectoris and Ischemic Heart Disease.  
Although the significant results did not always occur in the expected group, the Findings 
Group results may still exhibit a Health Certificate Effect. The increased risk of not attending 
for DM and COPD may correspond to the tenets behind the HBM and demonstrates a lack of 
a ‘trigger’ described by Rosenstock. The Non-Attendee members in the sample show an 
increased risk in two diseases that are highly correlated to lifestyle factors and demonstrates 
that this group is a health risk group. The Negative Findings group did show an increased risk 
of Hypertension on the outpatient side when the Interaction variable was included as well as 
for Diabetes Mellitus on the Outpatient side; these results were both at the highest 
significance level. One could expect that when tracking the risk of giving a screening, the 
Negative Results group and the Non-Attendee do present increased risk when the screening 
interaction with time is added for Diabetes Mellitus and Hypertension. If the time following 
the screening were increased, the trend could be better followed; there was only a 1 to 3-year 
follow-up from the screening ‘shock’.  
There is similarly another possibility that the Negative Findings group should not be the 
group of concern. These results may actually show that those in the Negative Findings group 
may in fact be the healthiest. It could quite possibly be that the Non-Attendee group should be 
the group requiring the most attention. Using tenets of the HBM and Rosenstock, one could 
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say that those in the Non-Attendee group may view themselves as being in good health. The 
results do show that the Non-Attendee group is at increased risk for DM and COPD 
complications, which are strongly correlated to lifestyle choices.  
9.1  Limitations 
The time length after screening presents a large challenge for accurately presenting the results 
and whether a Health Certificate Effect is present regardless of the significant results in the 
disease groups. A follow up of more years after the initial screening would enable a stronger 
and more accurate reporting of the time trends.  
This study did not account for deaths, part of this reason was that the number of dead was so 
small and the primary concern in this study was the effect of the various independent 
variables on the dependent disease group variables. When one considers the relatively short 5-
year survival rate of those diagnosed with CRC, there is a strong possibility that those with a 
CRC result from the screening trial would not as many as the initial 41 patients at the end of 
the data period. By not including death, the incidence of the various disease groups could 
appear higher than in reality or a death may be inaccurately reported as ‘no disease’ present 
for that year. However, because all the findings groups were measured the same way the risk 
of inflating or deflating the number of disease cases would be shared and most likely would 
not change the regression results a great deal. Similarly, the CRC-invited group, which would 
most likely have the most deaths did not have significant results. 
The data was a combination of dataset from many sources. One challenge was how part of the 
data was written using the ICD-9 coding and some used the ICD-10 coding, while all was 
done to match the coding together there is some risk that corresponding codes could have 
been missed. All was done to stay consistent and the codes used are listed in Appendix I with 
the equivalents used throughout the study’s progression. Further, as new diagnostic tools 
become available for detecting disease become available, the criteria for coding a disease 
risks changing as well. An example of this was in the diagnosis of Acute Myocardial 
Infarction that changed following the use of an ECG. The World Health Organisation has 
made amendments to the ICD-9 coding by providing supplements, however there was an 
additional code used in the ICD-9 called Old Myocardial Infarction, this was included and 
recorded as Acute Myocardial Infarction in this study; it is unclear how many patients this 
might have affected.  
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The selection of diseases related to the heart and circulatory system proved to be problematic. 
Both Angina Pectoris and Acute Myocardial Infarction are forms of Ischemic Heart Disease 
so it could be argued that diseases in this category could have been counted three times. All 
three diseases are a result of the building of plague in the main arteries and heart valves, 
however each of the three diseases manifested themselves differently and each has different 
treatment and health outcomes. For example, Angina Pectoris is non-fatal and is largely 
characterized by stress-induced pain, while an Acute Myocardial Infarction is a sudden and 
often fatal bout of pain caused by inadequate nutrients coming to the heart. It is also possible 
to have Ischemic Heart Disease and not experience an Acute Myocardial Infarction or have an 
Angina Pectoris episode. Since the three diseases were coded differently in the ICD-9 and 10 
from each other, there were numerous instances where only one of the diseases was coded in 
the same patient and that the study was largely based upon reason for inpatient and outpatient 
care, this did not appear to be that great of a problem.  
The Excluded findings group provided a challenge within this study in that the majority of 
disease groups selected for this study where conditions within the NORCCAP trial’s 
exclusion criteria. For this reason, the Exclusion group had highly significant results in all 
lifestyle-related disease groups and their risk of complications where higher than controls. 
The conclusions to draw from this group are difficult to interpret since the exclusion group is 
small and their initial health issues led to them being excluded from the NORCCAP trial. 
Due to the use of a Logistic Panel Regression, many of the categorical variables had to be 
changed into binary coding, for example, the Income Group had to change to each income 
level being separated and then coded as zero for ‘not present’ and 1 for ‘present’. While this 
was a simple method to prepare the data, there was a risk of over-simplifying and increasing 
the size of outputs from the regression. A number of assumptions had to be made using this 
binary method, particular in the Interaction variables. A patient who was invited to screening 
was indentified by a ‘1’, while the remaining controls where indentified using a ‘0’. An 
invited participant was assigned a ‘1’ from the time of their screening through to the end of 
the sample year of 2003. While this would report changes between years within the same 
patient, there is of course a risk of patient having numerous cases of the diseases within the 
same year; this makes changes hard to report and difficult to track. A more dynamic model 
instead of a binary model may show different findings. 
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9.2  Strengths  
This study presents a simple method to track and measure potential adverse effects of 
undertaking a mass-screening program for CRC. A great deal of literature has been presented 
about concerns about the Health Certificate Effect and for the most part it has been only 
discussed, no study has attempted to demonstrate it using statistical methods.  
The methods in this study could be easily transferred and used to evaluate other screening 
programs, specifically in terms of tracking changes over the years with a given dependent 
variable of concern within a single patient. The use of a panel data method enables the times 
series to be easily tracked within each patient rather easily. Similarly, by isolating variables in 
a binary manner, changes were simple to see and the data was easy to prepare.  
The interaction variable used to track a change in disease patterns within each patient 
following the results from the findings group is a strong method to determine whether 
unexpected effects could be seen in the given screening program studied. With a longer study 
period and a sample over a greater number of years, it would be a suitable model to 
investigate trends and a good method to test for the Health Certificate Effect.  
The socioeconomic factors that were discussed in the Theoretical portion of this study were 
confirmed by the results in this study. There is overwhelming evidence drawn from the results 
of this study that those with education that is of 14 years and above is a highly significant 
variable in reducing risk in each of the six disease groups. There is also a strong correlation 
between income and complications associated with the disease groups. Those in the 100,000 
to 199,999 NOK group were at a higher risk than controls in the Hypertension, COPD, 
Angina Pectoris, and Ischemic Heart Disease groups. Similarly, as income increases, the risk 
of disease decreases. These factors cannot be controlled, however it does demonstrate that 
even in a society with universal health care, these factors are still a highly significant 
variables within screening (Sreenivasan 2007) and lifestyle-related disease incidence. 
These results also show that existing methods used to evaluate screening programs are at risk 
for missing all costs and consequences. In the scope of this study, areas of potential costs 
were demonstrated based upon a screening result alone. Changes in behaviour and risk do 
occur following screening. The work of Howard and colleagues has identified cost savings in 
lifetime treatment costs in those with detected polyps than undetected; one area that they were 
unable to analyze however was net cost of screening (2009). By adding the lifestyle related 
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disease component from this study, determining a better estimate for net CRC screening costs 
could be partly achieved.  
9.3  Future Study and Implications 
A common criticism from the literature concerning undertaking a mass screening program has 
to do with the adverse implications that could occur within the screened group. A professional 
and randomized standard to carrying-out a trial must be maintained which at times requires 
the necessity of determining the effectiveness of the method of the study and providing the 
educational information needed for the participants to understand the results. It is the 
misinterpretation of the results that can lead to adverse events following the screening results.  
Studies by Tymstra and Bielemen (1987) and Larsen et. al. (2006a) have pointed to 
unintended consequences following mass screening. The solution advised by Rosenstock 
(2005) and the Health Belief Model (Janz & Becker 1984) has been to provide the necessary 
information needed for the screening participants to understand the results. There is of course 
a trade-off between the amount of information given before and after the trial by those 
running the screening program and the amount of resources available to do so while still 
controlling costs.  
Future studies could explore the Cost-Effectiveness component further. To do so, one would 
need to identify the costs associated with undertaking a mass-screening program and then 
determine the amount of information needed in order for patients to fully understand their 
results with their associated costs. Further, the results of this study would be used to examine 
the DRG costs associated with the disease groups. By determining the costs to treat the 
adverse events, there would be evidence to demonstrate both the risk of requiring treatment 
for the disease groups in question and the additional health costs associated with treating the 
other disease groups based upon a screening result. The cost component could also be 
explored over the years of the trial and following the trial. The conclusions drawn from 
adding the cost component would provide a better estimate of what costs are associated with 
mass screening and the adverse event costs.  
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10 Conclusion 
This thesis project aimed to determine whether outcomes of a mass screening could have an 
effect on life-style related diseases. In working to answer this question a methodology was 
created to track changes in disease related admissions to either inpatient or outpatient health 
care.  
It was hypothesized that a potential Health Certificate Effect could be present where patients 
who had negative results in their CRC screening may interpret the result as meaning that they 
are healthy. The assumption was that patients who did not believe that they were unhealthy 
would continue their same lifestyle choices, as they had no ‘shock’ to make them think 
otherwise. In this study, it was hypothesized the patients who were invited to the screening 
but did not attend and those who had a negative test would be at increased risk for other life-
style related diseases. The results did show that a Health Certificate Effect might be present in 
the Diabetes Mellitus, Hypertension and COPD disease groups. When compared to the 
Control group patients in the Negative Screening Result Group and the Non-Attendee group, 
required more health care for those conditions and the risks did change when following their 
screening test. However these results were not consistent between the Findings and 
Interaction group so there is the possibility, that in some cases those patients with a Negative 
Finding might in fact be in good health.  
The statistical method used and the framework in this study could be a good tool to use when 
seeking to evaluate indirect costs associated with mass screening programs.  
 
 
 
 
 
 
60 
 
References: 
Atkin WS. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline 
findings of a UK multicentre randomised trial. The Lancet (2002): 359 pp. 1291-1300. 
Bretthauer M, Gondal G, Larsen IK, Carlsen E, Eide TJ, Grotmol T, Skovlund E, Tveit KM, 
Vatn MH, Hoff G. Design, Organization and Management of a Controlled Population 
Screening Study for Detection of Colorectal Neoplasia. The Scandinavian Journal of 
Gastroenterology (2002): 5 pp. 569-573. 
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the 
Economic Evaluation of Health Care Programmes: Third Edition. Oxford University Press, 
Oxford 2005. 
Fox J. Applied Regression Analysis, Linear Models, and Related Methods. SAGE 
Publications, Thousand Oaks 1997. 
Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian Colorectal 
Cancer Prevention (NORCCAP) Screening Study: Baseline Findings and Implementations for 
Clinical Work-up in Age Groups 50-64 Years. Scand. J. Gastroenterol. (2003): 6 pp. 635-642. 
Hardcastle JD, Armitage NC, Chamberlain J, Amar SS, James PD, Balfour TW. Fecal Occult 
Blood Screening for Colorectal Cancer in the General Population: Results of a Controlled 
Trial. Cancer (1986): 58 pp. 397-403. 
Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James 
PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for 
colorectal cancer. The Lancet (1996): 348 pp. 1472-1477. 
Hoff G, Foerster A, Vatn MH, Gjone E. Epidemiology of Polyps in the Rectum and Sigmoid 
Colon: Histological Examination of Resected Polyps. Scand. J. Gastroenterology (1984): 20 
pp. 677-683. 
Hoff G, Vatn M, Gjone E, Larsen S, Sauar J. Epidemiology of Polyps in the Rectum and 
Sigmoid Colon: Design of a Population Screening Study. Scand. J. Gastroenterology (1985): 
20 pp. 351-355. 
Hoff G, Vatn MH, Larsen S. Relationship between Tobacco Smoking and Colorectal Polyps. 
Scand. J. Gastroenterology (1987): 22 pp. 13-16. 
Hoff G. Colorectal Polyps: Clinical Implications – Screening and Cancer Prevention. Scand. 
J. Gastroenterology (1987): 22 pp. 769-775. 
Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of 
screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from 
the Telemark Polyp Study 1983-1996. European Journal of Cancer Prevention (2001): 10 pp. 
131-137. 
Hoff G. CRC Screening: Review of the Evidence and Suggestions on When and How to 
Move on from Randomized Trials to Screening Programmes. Scand. J. Gastroenterol. (2004): 
2 pp. 99-103. 
61 
 
Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley-Interscience Publication, 
New York 1989. 
Howard DH, Tangka FK, Seeff LC, Richardson LC, Ekwueme DU. The Impact of Detection 
and Treatment on Lifetime Medical Costs for Patients with Precancerous Polyps and 
Colorectal Cancer. Health Economics (2009): 18 pp. 1381-1393.  
Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost 
and quality of life up to the year 2017. Acta Oncologica (1997): 36 (Suppl. 1) pp. S1-S60. 
Imperiale, TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of Advanced 
Proximal Neoplasms in Asymptomatic Adults According to the Distal Colorectal Findings. 
NEJM (2000): 343(3) pp. 169-174. 
Janz NK, Becker MH. The Health Belief Model: A Decade Later. Health Education & 
Behavior (1984): 11(1) pp. 1-47. 
Janz N, Wren PA, Schottenfeld D, Guire KE. Colorectal cancer screening attitudes and 
behavior: a population-based study. Preventative Medicine (2003): 37 pp. 627-634. 
Kronborg O, Fenger C, Olsen J. Randomised study of screening for colorectal cancer with 
faecal occult blood testing. The Lancet (1996): 348 pp. 1467-1471. 
Kumar P, Clark M. Kumar & Clark’s Clinical Medicine; Seventh Edition. Saunders Elsevier, 
London 2009. 
Larsen IK, Grotmol T, Bretthauer M, Gondal G, Huppertz-Hauss G, Hofstad B, Efskind P, 
Jørgensen A, Hoff G. Continuous Evaluation of Patient Satisfaction in Endoscopy Centres. 
Scand. J. Gastroenterology (2002): 7(37) pp. 850-855. 
Larsen IK, Grotmol T, Almendingen K, Hoff G. Lifestyle characteristics among participants 
in a Norwegian colorectal cancer screening trial. European Journal of Cancer Prevention 
(2006a): 15 pp. 10-15.  
Larsen IK, Grotmol T, Almendingen K, Hoff G. Lifestyle as a predictor for colonic neoplasia 
in asymptomatic individuals. BMC Gastroenterology (2006b): 6(5).  
Larsen IK, Grotmol T, Almendingen K, Hoff G. Impact of Colorectal Cancer Screening on 
Future Lifestyle Choices: A Three-Year Randomized Controlled Trial. Clinical 
Gastroenterology and Hepatology (2007): 5(4) pp. 477-483. 
Lieberman DA. Cost-effectiveness Modell for Colon Cancer Screening. Gastroenterology 
(1995): 109 pp. 1781-1790. 
Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of Colonoscopy 
to Screen Asymptomatic Adults for Colorectal Cancer. NEJM (2000): 343(3) pp. 162-168. 
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. 
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood. HEJM 
(1993): 328(19) pp. 1365-1371.  
62 
 
McPhee SJ, Papadaki MA. Current Medical Diagnosis & Treatment: 2008 47th Edition. LM 
Tierney ed. McGraw Hill Medical, London 2008. 
Moller B, Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M. Prediction of 
cancer incidence in the Nordic countries up to the year 2020. European Journal of Cancer 
Prevention (2002): 11 (suppl. 1) pp. S1-S96. 
NORDCAN. Cancer Stat Fact Sheet – Colorectal Cancer in Norway (2010). URL: 
http://www-dep.iarc.fr/NORDCAN/english/StatsFact.asp?cancer=520&country=578 
Robinson MHE, Hardcastle JD, Moss SM, Amar SS, Chamberlain JO, Armitage NCM, 
Scholefield JH, Mangham CM. The risks of screening: data from the Nottingham randomised 
controlled trial of faecal occult blood screening for colorectal cancer. Gut (1999): 45 pp. 588-
592. 
Rosenstock IM. Public Response to Cancer Screening and Detection Programs: Determinants 
of Health Behavior. J. Chron. Dis. (1963): 16 pp. 407-418. 
Rosenstock IM. Why People Use Health Services. Milbank Quarterly (2005): 44(3) pp. 1-32. 
Segnan N, Senore C, Andreoni B, Aste H, BonellI L, Crosta C, Ferraris R, Gasperoni S, 
Penna A, Risio M, Rossini FP, Sciallero S, Zappa M, Atkin WS. Baseline Findings of the 
Italian Multicenter Randomized Controlled Trial of ”Once-only Sigmoidoscopy” – SCORE. 
Journal of the National Cancer Institute (2002): 94(23) pp. 1763-1772. 
Sreenivasan G. Health Care and Equality of Opportunity. Hastings Center Report (2007): 
37(2) pp. 21-31. 
Stata: Release 10 – Longitudinal/Panel Data. Stata Press Publication, College Station TX 
2007. 
Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH. The Effect of Attending a Flexible 
Sigmoidoscopic Screening Program on the Prevelance of Colorectal Adenomas at 13-Year 
Follow-Up. American Journal of Gastroenterology (2001): 96(6) pp. 1901-1907. 
Thiis-Evensen E, Seip B, Vatn MH, Hoff GS. Impact of a colonoscopic screening 
examination for colorectal cancer on later utilization of distal GI endoscopies. Gastrointestinal 
Endoscopy (2006): 64(6) pp. 948-954. 
Towler B, Irwing L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the 
effects of screening for colorectal cancer using the fecal occult blood test, Hemoccult. BMJ 
(1998): 317 pp. 559-565. 
Tymstra T, Bieleman B. The Psychosocial Impact of Mass Screening for Cardiovascular Risk. 
Family Practice (1987): 4(4) pp. 287-290. 
Vatn MH, Hoff G. Colorectal Cancer Prevention: In Search of Risk Factors and Increased 
Effectiveness of Surveillance Programs. Scand. J. Gastroenterology (1989): 24 pp. 1025-
1030. 
63 
 
Whynes DK, Frew EJ, Edwards R, Atkin WS. Cost of Flexible Sigmoidoscopy Screening for 
Colorectal Cancer in the United Kingdom. International Journal of Technology Assessment in 
Health Care (2003): 2 pp. 384-395. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
Appendix I: New Coding for ICD­9 and ICD­10 
 
Diabetes Mellitus – ICD-9 250, ICD-10 E10-E14. 
 
Hypertension, Secondary Hypertension & Hypertensive Heart Disease – ICD-9 401, 402, 
405, ICD-10 I10, I11, I15. 
 
Chronic Obstructive Pulmonary Disease – ICD-9 496 & 492, ICD-10 J43 & J44. 
 
Angina Pectoris – ICD-9 413, ICD-10 I20. 
 
Acute Myocardial Infarction & Old Myocardial Infarction – ICD-9 410 & 412, ICD-10 I21. 
 
Ischemic Heart Disease Acute and Chronic – ICD-9 411 & 414, ICD-10 I25. 
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Appendix II: Proportions per 1000 patients 
listed by Disease Group and Age Group 
Diabetes Mellitus 
Diabetes Mellitus             
 Outpatient Inpatient 
Patients 50 - 54 Years             
 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003 
Control 0.091 0.684 0.919 1.137 0.572 0.814 0.214 0.244 0.374 0.340 0.298 0.512 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 8.333 8.333 
Attended - Positive Findings 0 0.396 0.528 0.925 0.396 0.528 0 0 0.132 0 0.264 0.132 
Attended - Negative Findings 0.045 0.608 0.653 0.923 0.765 0.833 0.158 0.180 0.158 0.135 0.315 0.360 
Non-Attendee 0.031 0.628 0.691 0.910 0.816 0.910 0.377 0.282 0.628 0.408 0.502 0.753 
Returned / Dead 0 0.667 0 0 0 0.667 0.667 0 0.667 0.667 0 1.333 
Excluded 0.752 1.504 3.008 1.504 2.256 2.256 2.256 2.256 4.511 0.752 1.504 1.504 
             
Patients 55 - 64 Years             
             
Control 0.104 0.795 1.036 1.137 0.704 0.762 0.397 0.436 0.603 0.595 0.471 0.625 
Attended - CRC 0 0 0 0 3.448 0 0 0 0 0 0 0 
Attended - Positive Findings 0 0.629 1.118 1.398 1.118 1.225 0.350 0.280 0.280 0.629 0.559 0.909 
Attended - Negative Findings 0.016 0.845 0.975 1.154 0.829 0.796 0.211 0.276 0.374 0.455 0.585 0.569 
Non-Attendee 0.235 1.543 1.517 1.413 1.177 1.020 0.785 0.811 1.230 1.047 0.916 0.785 
Returned / Dead 0 0.470 0 0 0.939 0.470 1.409 1.409 0 0.939 0 0.470 
Excluded 0 1.424 1.068 1.424 1.068 1.068 1.424 1.779 2.491 0.712 1.424 1.779 
 
Hypertension 
Hypertension             
 Outpatient Inpatient 
Patients 50 - 54 Years             
 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003 
Control 0.035 0.649 0.698 0.712 0.579 0.698 0.351 0.400 0.537 0.621 0.574 0.946 
Attended - CRC 0 0 0 0 8.333 0 0 0 0 8.333 8.333 8.333 
Attended - Positive Findings 0 0.793 1.057 0.793 0.396 0.925 0 0.396 0.528 0.132 0.925 0.925 
Attended - Negative Findings 0 0.653 0.630 0.765 0.968 0.743 0.315 0.203 0.270 0.495 0.608 0.945 
Non-Attendee 0.031 0.408 0.659 0.753 0.722 0.596 0.377 0.439 0.659 0.628 0.722 0.973 
Returned / Dead 0 0 0.667 0 0.667 0 2.000 0.667 0 1.333 0.667 1.333 
Excluded 0 1.504 0 0.752 0.752 0 0.752 1.504 3.008 4.511 1.504 3.008 
             
Patients 55 - 64 Years             
             
Control 0.069 0.958 0.987 1.313 0.850 0.792 0.669 0.858 1.030 1.091 1.091 1.455 
Attended - CRC 0 0 0 0 0 0 0 3.448 3.448 0 0 0 
Attended - Positive Findings 0.070 0.978 1.048 1.048 0.978 0.909 1.049 0.909 0.839 1.329 2.168 1.818 
Attended - Negative Findings 0.049 0.894 1.154 1.040 0.894 0.959 0.439 0.439 0.683 1.138 1.203 1.446 
Non-Attendee 0.105 0.654 0.628 1.125 0.994 0.759 0.680 0.994 1.361 1.439 1.151 1.439 
Returned / Dead 0 0 0.470 0 0.470 0 0.939 1.409 0.470 0 0 0 
Excluded 0 2.847 3.203 2.135 2.135 1.779 2.847 1.779 3.559 2.491 1.779 3.203 
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Chronic Obstructive Pulmonary Disorder 
COPD             
 Outpatient Inpatient 
Patients 50 - 54 Years             
 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003 
Control 0.030 0.281 0.354 0.456 0.305 0.430 0.126 0.156 0.226 0.235 0.202 0.319 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 0 
Attended - Positive Findings 0 0.661 0.264 0.396 0.528 0 0 0.264 0 0.132 0.264 0.396 
Attended - Negative Findings 0 0.248 0.180 0.180 0.225 0.248 0.023 0.180 0.135 0.135 0.113 0.315 
Non-Attendee 0.031 0.408 0.471 0.188 0.471 0.502 0.126 1.157 0.282 0.314 0.408 0.659 
Returned / Dead 0 0 0 0 0 0 0 0.667 0 0 0 0 
Excluded 0 0.752 0.752 2.256 2.256 3.008 0 0.752 0.752 2.256 1.504 3.008 
             
Patients 55 - 64 Years             
             
Control 0.049 0.608 0.740 0.850 0.562 0.663 0.291 0.428 0.540 0.452 0.425 0.644 
Attended - CRC 0 0 0 0 0 0 0 0 3.448 0 0 0 
Attended - Positive Findings 0 0.419 0.559 0.699 0.349 0.489 0.350 0.490 0.490 0.490 0.350 0.350 
Attended - Negative Findings 0.016 0.390 0.406 0.487 0.552 0.422 0.130 0.341 0.406 0.471 0.536 0.439 
Non-Attendee 0.052 0.680 0.732 0.654 0.785 0.759 0.497 0.863 0.680 0.837 0.837 0.968 
Returned / Dead 0 0.470 0 0 0.470 0.939 0 1.409 0.939 0 0.470 0.470 
Excluded 0 2.847 3.559 3.203 3.559 4.271 5.338 4.271 3.559 4.626 4.281 3.559 
 
Angina Pectoris 
Angina Pectoris             
 Outpatient Inpatient 
Patients 50 - 54 Years             
 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003 
Control 0.037 0.263 0.326 0.321 0.267 0.244 0.254 0.405 0.470 0.395 0.270 0.344 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 0 
Attended - Positive Findings 0 0.264 0.661 0.396 0.661 0.528 0.132 0.264 0.132 0.396 0.396 0.396 
Attended - Negative Findings 0.023 0.113 0.383 0.338 0.203 0.405 0.225 0.248 0.315 0.405 0.225 0.338 
Non-Attendee 0 0.314 0.314 0.534 0.251 0.251 0.188 0.408 0.408 0.251 0.251 0.377 
Returned / Dead 0 0.667 0 0 1.333 0.667 0.667 0.667 0 0 0 0 
Excluded 0 1.504 3.759 0.752 1.504 0.752 2.256 3.008 5.263 3.579 3.008 1.504 
             
Patients 55 - 64 Years             
             
Control 0.080 0.532 0.584 0.573 0.356 0.332 0.488 0.762 0.855 0.677 0.504 0.537 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 0 
Attended - Positive Findings 0 0.769 0.349 0.767 .0559 0.419 0.699 0.769 0.769 0.769 0.979 0.769 
Attended - Negative Findings 0.033 0.422 0.487 0.552 0.552 0.341 0.455 0.634 0.601 0.959 0.618 0.667 
Non-Attendee 0.105 0.392 0.680 0.523 0.471 0.392 0.890 1.204 1.020 1.073 0.654 0.811 
Returned / Dead 0 0.939 0.470 0.470 0.470 0 0.470 0.470 1.409 0.939 0.470 0 
Excluded 0 3.559 1.424 1.424 0.712 0.712 2.491 3.559 3.203 0.356 2.491 1.779 
 
Acute Myocardial Infarction 
Acute Myocardial Infarction             
 Outpatient Inpatient 
Patients 50 - 54 Years             
 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003 
Control 0.016 0.030 0.019 0.042 0.033 0.028 0.293 0.100 0.186 0.205 0.130 0.219 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 8.333 
Attended - Positive Findings 0 0 0 0 0 0 0.396 0 0.132 0 0.132 0.396 
Attended - Negative Findings 0.023 0 0.023 0.068 0.023 0.045 0.135 0.045 0.135 0.225 0.113 0.293 
Non-Attendee 0.031 0 0.063 0 0 0 0.188 0.157 0.188 0.157 0.188 0.157 
Returned / Dead 0 0 0 0 0 0 0.667 0 0 0 0 0 
Excluded 0.752 0 0.752 0 0 0 3.759 0 1.504 2.256 0 0.752 
             
Patients 55 - 64 Years             
             
Control 0.044 0.047 0.063 0.104 0.052 0.028 0.471 0.200 0.271 0.304 0.219 0.299 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 0 
Attended - Positive Findings 0 0 0.069 0 0.280 0.070 0.490 0.140 0.140 0.350 0.629 0.350 
Attended - Negative Findings 0.016 0 0.016 0.065 0.016 0.033 0.228 0.081 0.244 0.195 0.341 0.439 
Non-Attendee 0.026 0 0.026 0.078 0.026 0.026 0.706 0.340 0.419 0.314 0.445 0.550 
Returned / Dead 0 0 0 0 0 0 1.409 0.939 0 0 0 0 
Excluded 0 0 0 0.356 0 0 2.135 1.068 1.504 0.356 0.356 0 
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Ischemic Heart Disease 
Ischemic Heart Disease             
 Outpatient Inpatient 
Patients 50 - 54 Years             
 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003 
Control 0.047 0.330 0.619 0.553 0.437 0.572 0.405 0.319 0.549 0.381 0.372 0.512 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 0 
Attended - Positive Findings 0 0.264 0.396 0.396 0.396 1.189 0 0.264 0.264 0.264 0.264 0.793 
Attended - Negative Findings 0 0.225 0.473 0.450 0.405 0.585 0.270 0.225 0.293 0.338 0.248 0.428 
Non-Attendee 0.094 0.408 0.722 0.596 0.345 0.659 0.251 0.282 0.502 0.282 0.408 0.502 
Returned / Dead 0 0 0.667 0 0 0 0.667 0.667 0.667 0 0.667 0 
Excluded 0 3.759 6.767 6.015 3.759 5.263 3.008 1.504 4.511 3.759 3.759 4.511 
             
Patients 55 - 64 Years             
             
Control 0.115 0.614 0.962 0.830 0.551 0.767 0.789 0.641 1.061 0.806 0.773 0.874 
Attended - CRC 0 0 0 0 0 0 0 0 0 0 0 0 
Attended - Positive Findings 0.210 0.559 1.188 0.767 0.699 0.559 0.769 0.909 0.909 0.699 1.399 1.329 
Attended - Negative Findings 0.033 0.471 0.845 0.650 0.536 0.764 0.455 0.471 0.585 0.666 0.748 0.910 
Non-Attendee 0.105 0.706 1.046 0.706 0.445 0.602 0.916 0.942 1.073 0.890 1.047 1.282 
Returned / Dead 0 0.470 0.470 0.470 0.470 0 0.939 1.409 0.939 0.470 0.470 0 
Excluded 0.712 2.847 5.338 3.203 2.491 1.424 4.271 4.626 5.338 2.847 3.759 1.779 
 
